Contrasting Two Prophylactic Dysphagia Interventions for Patients with Head and Neck Cancer Treated with Radiotherpy with or without Adjunctive Chemotherapy by Slovarp, Laurie
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2015 
Contrasting Two Prophylactic Dysphagia Interventions for 
Patients with Head and Neck Cancer Treated with Radiotherpy 
with or without Adjunctive Chemotherapy 
Laurie Slovarp 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Slovarp, Laurie, "Contrasting Two Prophylactic Dysphagia Interventions for Patients with Head and Neck 
Cancer Treated with Radiotherpy with or without Adjunctive Chemotherapy" (2015). Graduate Student 
Theses, Dissertations, & Professional Papers. 4615. 
https://scholarworks.umt.edu/etd/4615 
This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
Running head: TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC 
i 
 
 
CONTRASTING TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR PATIENTS 
WITH HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY WITH OR WITHOUT 
ADJUNCTIVE CHEMOTHERAPY 
By 
 
Laurie Jean Slovarp 
 
M.S. Arizona State University, Tempe, AZ 2000 
B.S. Idaho State University, Pocatello, ID 1996 
 
Dissertation  
 
presented in partial fulfillment of the requirements for the degree of  
 
Doctor of Philosophy  
in Independent Interdisciplinary Studies 
 
The University of Montana 
Missoula, MT  
 
Approved by:  
 
Sandy Ross, Dean of the Graduate School 
Graduate School 
 
Catherine Off, Ph.D., Co-Chair 
Communicative Sciences and Disorders  
 
Julie Liss, Ph.D., Co-Chair 
Speech and Hearing Sciences , Arizona State University  
 
Allen Szalda-Petree, Ph.D. 
Department of Psychology  
 
Brian Steele, Ph.D. 
Department of Mathematical Sciences 
 
Jeffrey Haller, M.D. 
Rocky Mountain Ear, Nose, and Throat, Missoula, MT 
 
Peter Belafsky, M.D., Ph.D. 
UC Davis Health System, Sacramento, CA  
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
ii 
 
Acknowledgements  
 The last five years have been an enormous challenge and one that at times I was not certain I 
was going to be able to complete. It would not have been possible without the help and support of 
many individuals.   
I would like to express my sincere appreciation to my committee co-chairs, Dr. Catherine Off 
and Dr. Julie Liss. I initially worked with Dr. Liss when I attended Arizona State University for my 
Master’s degree in Speech and Hearing Sciences. She was a significant mentor and role-model at that 
time and I am so thankful that she agreed to take on that role once again for my Ph.D. studies. I thank 
Dr. Off for her initial support and encouragement in pursuing an Independent Interdisciplinary Ph.D. 
(IIP). Dr. Off dedicated a great deal of time in the initial phases of the IIP application process, which 
included mentoring me in writing the dissertation prospectus, creating an interdisciplinary plan of 
study, and advocating for my acceptance. I thank both Dr. Off and Dr. Liss for their support, 
mentorship, and encouragement in the process of completing my dissertation study.  
I am also thankful for Dr. Brian Steele and Dr. Allen Szalda-Petree, both of whom agreed to 
serve on my committee after knowing me only because of my attendance in a couple of their courses. 
Thank you, Dr. Steele for assisting with statistical analysis.  Thank you, Dr. Allen Szalda-Petree for 
assisting with study design.  
I am particularly grateful for Dr. Jeffrey Haller and Dr. Peter Belafsky, both of whom took time 
out of their very busy physician schedules to serve on my committee. Dr. Peter Belafsky has been an 
invaluable and inspirational mentor, both academically and clinically. His dedication to his work in the 
area of swallowing disorders, and his compassion for his patients, are truly inspirational. After 
consulting with me one time regarding a difficult case, Dr. Belafsky selflessly invited me to observe 
him and his team at the UC Davis Voice and Swallowing Center. That one-week experience left an 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
iii 
 
immense impression on me and gave me a desire to become a leading expert in the area of swallowing 
disorders. That desire eventually led me to the path of a Ph.D.  
I am equally grateful for Dr. Jeffrey Haller who has always treated me as a respected colleague 
in the medical community and has placed his confidence in me for caring for his patients with 
swallowing and voice disorders for the past several years.  He also assisted with patient recruitment for 
this study and continually advocates for my work to his patients.  
I must also thank my family for their support and sacrifice during this process.  My husband, 
Kevin, has frequently taken up the slack in our family responsibilities so that I could accomplish this 
goal. My children, Luke and Brinlee, have loved me despite my frequent absence physically and/or 
mentally. They have also learned to be patient and flexible with the meaning of “just a couple more 
minutes of work.” I also am grateful for my parents, sister, in-laws, and extended, who have always 
been my biggest fans and encouraged me to pursue my academic goals. Lastly, I am grateful for my 
faith, which has taught me the importance and reward of caring for and serving others, rather than 
myself.  
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
iv 
 
 
TABLE OF CONTENTS 
 
Acknowledgements ....................................................................................................................................... ii 
Table of Terms and Abbreviations .............................................................................................................vii 
List of Tables .............................................................................................................................................. viii 
List of Figures ................................................................................................................................................ x 
Abstract ......................................................................................................................................................... xi 
Chapter 1: Introduction .................................................................................................................................. 1 
Statement of the Problem .......................................................................................................................... 5 
Purpose ....................................................................................................................................................... 5 
Research Questions and Hypotheses: ....................................................................................................... 6 
Chapter 2: Literature Review ........................................................................................................................ 8 
Swallowing Function ................................................................................................................................ 8 
Dysphagia .................................................................................................................................................. 9 
Interdisciplinary Approach to Dysphagia Management .......................................................................... 9 
Swallowing Assessment .......................................................................................................................... 10 
Swallowing Treatment ............................................................................................................................ 11 
Range of motion (ROM) exercises .................................................................................................... 12 
Oral and pharyngeal strengthening exercises .................................................................................... 14 
The Interaction between Radiation Therapy and Chemotherapy ......................................................... 17 
Fractionation ........................................................................................................................................ 18 
Intensity modulated radiation therapy ................................................................................................ 18 
Image-guided radiotherapy ................................................................................................................. 19 
RT/CRT Toxicity-Induced Dysphagia ................................................................................................... 19 
Quality of Life During and Following RT/CRT for HNC .................................................................... 22 
Treatment Models for Management of RT/CRT-Toxicity-Induced Dysphagia .................................. 25 
The Reactive Model ............................................................................................................................ 25 
The Educational/Monitoring Model ................................................................................................... 26 
The Prophylactic Model. .................................................................................................................... 26 
Chapter 3: Methodology .............................................................................................................................. 40 
Recruitment .............................................................................................................................................. 40 
Measures .................................................................................................................................................. 41 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
v 
 
Instrumental swallowing assessment ................................................................................................. 41 
Study-specific nutrition and pain questionnaire ................................................................................ 41 
Functional Oral Intake Scale (FOIS):................................................................................................. 42 
MD Anderson Dysphagia Inventory (MDADI). ............................................................................... 42 
Eating Assessment Tool-20 (EAT-20) ............................................................................................... 43 
Combination Prophylactic Swallowing Exercises (C-PSE) ............................................................. 47 
Indirect Prophylactic Swallowing Exercises (ID-PSE) ......................................................................... 47 
Training Phase ..................................................................................................................................... 48 
Treatment phase .................................................................................................................................. 48 
Post-treatment phase ........................................................................................................................... 48 
Participants ............................................................................................................................................... 49 
Group Demographics and Cancer Characteristics ................................................................................. 50 
Baseline Outcomes .................................................................................................................................. 52 
Statistical Analysis .................................................................................................................................. 54 
Chapter 4: Results ........................................................................................................................................ 56 
Compliance .............................................................................................................................................. 56 
Oral Intake ............................................................................................................................................... 58 
Swallowing Function .............................................................................................................................. 63 
Eating Assessment Tool-20 (EAT-20). .............................................................................................. 63 
MD Anderson Dysphagia Inventory (MDADI). ............................................................................... 69 
Swallowing Pain ...................................................................................................................................... 74 
Chapter 5: Discussion .................................................................................................................................. 76 
Compliance .............................................................................................................................................. 77 
Oral Intake ............................................................................................................................................... 78 
Functional Oral Intake Scale .............................................................................................................. 78 
PEG-tube dependence ......................................................................................................................... 79 
Swallowing Function .............................................................................................................................. 79 
Swallowing Pain ...................................................................................................................................... 81 
Limitations ............................................................................................................................................... 82 
Chapter 6: Conclusions ................................................................................................................................ 86 
Clinical Implications ............................................................................................................................... 86 
Future Directions ..................................................................................................................................... 88 
Appendices ................................................................................................................................................. 116 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
vi 
 
Appendix A: Permission to be Contacted form ................................................................................... 116 
Appendix B: Nutrition and Pain Questionnaire ................................................................................... 117 
Appendix C: MD Anderson Dysphagia Inventory  ............................................................................. 118 
Appendix D: Eating Assessment Tool ................................................................................................. 120 
Appendix E: Subject Informed Consent form ..................................................................................... 121 
Appendix F: Authorization for Access to Personal Health Information ............................................ 128 
Appendix G: C-PSE exercise instructions ........................................................................................... 130 
Appendix H: ID-PSE exercise instructions .......................................................................................... 131 
Appendix I: C-PSE exercise tracking sheet ......................................................................................... 132 
Appendix J: ID-PSE exercise tracking sheet ....................................................................................... 133 
 
 
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
vii 
 
Table of Terms and Abbreviations 
ASHA American Speech-Language-Hearing Association 
Aspiration When food or liquid enters the airway below the level of the glottis 
BMI Body Mass Index 
CRT Chemoradiation therapy 
C-PSE Prophylactic swallowing exercises consisting of direct and indirect exercises 
DNA Deoxyribonucleic acid 
EAT Eating Assessment Tool 
Enteral 
nutrition  Nutrition delivered via a feeding tube 
EORTC QLQ-
C30 
European Organization  for Research and Treatment of Cancer Quality of 
Live Questionnaire 
FACT-H&N Functional Assessment of Cancer Therapy-Head and Neck 
FEES Fiberoptic endoscopic evaluation of swallowing 
FOIS Functional Oral Intake Scale 
HADS Hospital Anxiety and Depression Scale 
HIPAA Health Insurance Portability and Accountability Act  
HNC Head and neck cancer 
HNSCC Head and neck squamous cell carcinoma 
HPV Human papilloma virus 
HRQOL Health related quality of life 
ID-PSE 
Prophylactic swallowing exercises consisting solely of indirect swallowing 
exercises 
IRB Institutional Review Board 
MASA Mann Assessment of Swallowing Ability  
MBS Modified barium swallow study 
MDADI M.D. Anderson Dysphagia Inventory 
MRI Magnetic Resonance Imaging 
PAS Penetration-Aspiration Scale 
PSE Prophylactic swallowing exercises 
PEG Percutaneous Endoscopic Gastronomy 
PSS-H&N Performance Status Scale for Head & Neck Cancer 
QOL Quality of Life 
QLQ-H&N35 Quality of Life Questionnaire-Head and Neck Cancer Module 
RT Radiation Therapy 
SLP Speech Language Pathologist 
TNM Tumor Node Metastasis 
 
 
  
  
  
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
viii 
 
List of Tables 
1 Summary of prior studies on prophylactic swallowing exercises and key findings………........ 38 
2 EAT-20 items separated into physical, emotional, and functional subscales………………...... 44 
3 Chronbach’s alpha coefficients measuring internal consistency within the EAT-20 subscales 44 
4 Common pathophysiologic impairments due to RT/CRT toxicity, the exercises that target 
them, and prior PSE studies that have included each of the exercises………………………… 
 
46 
5 Demographics and baseline data of participants including age, gender, tumor size, nodal 
disease, cancer stage, tumor site, PEG use, FOIS, EAT-20 scores at baseline………………… 
 
51 
6 Baseline outcome data including percentage PEG use, swallowing pain, FOIS, and EAT-20… 53 
7 Total group means contrasted with patient 13’s individual scores on baseline measures …....... 53 
8 Mean compliance rates, standard deviations, and ranges pre-RT/CRT and weekly during 
RT/CRT……………………………………………………………………………………… 
 
57 
9 Mean compliance rates for the first half and second half of the RT/CRT phase as well as total 
compliance per group………………………………………………………………………... 
 
57 
10 Mean PEG use, standard deviations, and ranges at baseline, during RT/CRT, and following 
RT/CRT……………………………………………………………………………………... 
 
60 
11 Mean FOIS scores, standard deviations, and ranges at baseline, during RT/CRT, and 
following RT/CRT…………………………………………………………………………… 
 
60 
12 PEG-tube discontinuation rates at the end of RT, one month post-RT/CRT, two months post-
RT/CRT, and three months post-RT/CRT…………………………………………………… 
 
63 
13 Mean EAT-20-Total and EAT-20 subscale scores at the end of RT/CRT and during the post-
RT/CRT phase………………………………………..…………………………………….. 
 
66 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
ix 
 
14 Mean difference scores on the EAT-20 subscales at one month post-RT/CRT and three 
months post-RT/CRT………………………………………………………………………… 
 
68 
15 Mean ranks for EAT-20 subscale difference scores at one month post-RT/CRT and three 
months post-RT/CRT………………………………………………………………………… 
 
69 
16 Mean MDADI scores at the final-RT session, one month post-RT/CRT, and three months 
post-RT/CRT………………………………………………………………………………… 
 
71 
17 Mean ranks for MDADI subscale scores at the final-RT session, one month post-RT/CRT, 
and three months post-RT/CRT……………………………………………………………... 
 
72 
18 Mean swallowing-pain scores, standard deviations, ranges, and mean ranks at RT 12-14, RT 
23-25, Final RT, one month post-RT/CRT, and three months post-RT/CRT…………………. 
 
75 
 
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
x 
 
List of Figures  
 
1 Breakdown of patient enrollment and attrition at each data time point………….………... 50 
 
2 
 
Mean compliance per group from pre-RT/CRT through week seven of RT/CRT….……. 58 
 
3 
 
Mean compliance per group for the first and second half of RT/CRT…...……………….. 58 
 
4 
 
Mean PEG tube use from baseline to three months post-RT/CRT.………………………. 61 
 
5 
 
Mean FOIS scores from baseline to three months post-RT/CRT……………..………….. 61 
 
6 
 
Percent of patients who discontinued PEG-tube use at the final-RT, one month, two months, and  
 
three months, post RT/CRT………………………………………………………………..……. 63 
 
7 
 
Mean EAT-20 subscale scores during RT/CRT……………………………….…………  65 
 
8 
 
Mean EAT-20-P scores during the post-RT/CRT phase………………………….…………..….. 66 
 
9 
 
Mean EAT-20-P scores during the post-RT/CRT phase with patient 13 excluded……….…….… 66 
  
10 
 
Mean EAT-20-F scores during the post-RT/CRT phase………………………....……………….. 67 
 
11 
 
Mean EAT-20-F scores during the post-RT/CRT phase with patient 13 excluded……….……….. 67 
 
12 
 
Mean EAT-20-E scores during the post-RT/CRT phase………………......…………...…………. 67 
  
 13 
 
Mean EAT-20-E scores during the post-RT/CRT phase with patient 13 excluded…….....……….. 67 
 
14 
 
MDADI scores at the final RT/CRT session………....…………………………………………… 70 
 
15 
 
Mean MDADI-Global post-RT/CRT scores……………………………....……………………… 73 
 
16 
 
Mean MDADI-Emotional post-RT/CRT scores……………………….....………...…………….. 73 
 
17 
 
Mean MDADI-Functional post-RT/CRT scores……………………………………………….....  73 
 
18 
 
Mean MDADI-Physical post-RT/CRT scores……………………………………………………. 73 
 
19 
 
Mean swallowing pain scores per group at RT 12-14, RT 23-25, final-RT, one month post- 
 
RT/CRT, and three months post-RT/CRT………………………......………………………….. 75 
 
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
xi 
 
 
Abstract 
 
 
Slovarp, Laurie, Ph.D., Summer 2015                                                   Independent Interdisciplinary Studies 
 
Contrasting Two Prophylactic-Dysphagia Interventions for Patients with Head and Neck Cancer Treated 
with Radiotherapy with or without Adjunctive Chemotherapy 
 
Co-Chairperson: Catherine Off, Ph.D., CCC-SLP 
Co-Chairperson: Julie Liss, Ph.D.  
 
 
  Many patients with head and neck cancer (HNC) suffer from dysphagia caused by organ preserving 
regimens of radiation therapy with or without adjunctive chemotherapy. Prior research has shown a 
benefit of prophylactic dysphagia intervention; however, prior studies vary in terms of timing, dosage, 
and types of treatments prescribed. Additionally, compliance to prophylactic swallowing exercises 
(PSEs) has been poor and anecdotal evidence points towards swallowing pain as a cause of poor 
compliance. This prospective study investigated exercise compliance, oral intake, self-perceived 
swallowing function, swallowing-related quality of life, and swallowing-related pain for patients who 
received two different types of prophylactic swallowing interventions. A total of 18 participants 
partook of the study.  Nine patients completed only indirect swallowing exercises (exercises that do not 
require swallowing; ID-PSE group). The remaining nine patients completed a combination of indirect 
and direct swallowing exercises (exercises that require swallowing; C-PSE group). There were no 
significant differences between the groups at baseline or at any point during RT/CRT. The ID-PSE 
group performed significantly better than the C-PSE group at one month post-RT/CRT in swallowing 
function, as measured by the Eating Assessment Tool, and swallowing-related QOL, as measured by 
the MD Anderson Dysphagia Inventory. By three months post RT/CRT these differences were not 
present; however, at three months post the C-PSE group reported significantly less swallowing pain 
than the ID-PSE group. Between-group differences were not evident at any point in compliance or oral 
intake. Outcomes for both groups were comparable to prior PSE studies and better than outcomes 
reported in the literature in HNC patients who did not receive prophylactic intervention. This study is 
the first to investigate and provide preliminary evidence for the efficacy of a prophylactic swallowing 
intervention consisting solely of indirect swallowing exercises. Study limitations, clinical implications, 
and future directions are discussed.  
 
Key words: dysphagia, prophylactic swallowing exercises, head and neck cancer, radiotherapy, 
chemoradiation therapy, quality of life, pain, swallowing function  
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Chapter 1: Introduction 
Head and neck cancer (HNC) refers to malignant tumors of the oral cavity, pharynx, or larynx.  
It is the eighth most common cancer among men and 14th most common among women in the United 
States (Chaturvedi, Engels, Anderson, & Gillison, 2008). HNC is estimated to impact nearly 600,000 
patients per year and over 300,000 deaths (Marur, D'Souza, Westra, & Forastiere, 2010). The most 
common histological type of HNC is squamous cell carcinoma, which arises in the mucosal lining of 
the mouth, pharynx, or larynx.  Patients are usually diagnosed between 40 and 55 years of age.  A 
significant increase in the rate of HNC, specifically in the oropharynx (tonsil and tongue base area), has 
been documented in recent years (Marur et al., 2010).    
For decades, tobacco and alcohol use were the primary causes of HNC; however, 
approximately 40% to 80% of oropharyngeal cancers in the United States are now associated with the 
human papillomavirus (HPV; Marur et al., 2010; Sudhoff et al., 2011).  In fact, non-smokers who are 
HPV positive are now 15 times more likely to develop HNC than smokers (Sudhoff et al., 2011).  
Numerous types of HPV exist; however, the vast majority (>90%) of HPV-associated HNCs is caused 
by a single type--HPV 16 (Marur et al., 2010; Sudhoff et al., 2011).  While the incidence of head and 
neck cancer secondary to smoking has fallen steadily since the 1970s, HPV-associated HNC has been 
increasing steadily (Auluck et al., 2010; Marur et al., 2010; Sudhoff et al., 2011). One study estimated 
that if recent incident trends continue, the annual number of HPV-associated oropharyngeal cancer will 
surpass the annual number of cervical cancer by 2020 (Chaturvedi et al., 2011).  The most current 
studies of medical care costs for HPV-related oropharyngeal cancer estimate a cost of $306 million per 
year for the United States (Chesson et al., 2012) and $519 million per year for France (Borget, 
Abramowitz, & Mathevet, 2011). 
Fortunately, significant advances of the treatment of HNC have emerged in the past two 
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decades. Prior to the 1990s, the standard treatment for HNC was surgical dissection (with or without 
adjunctive radiation therapy), or radiation therapy (i.e., radiotherapy or RT) alone (Forastiere et al., 
2003a). This practice changed in the early 1990s when the Department of Veteran Affairs Laryngeal 
Cancer Study Group showed that chemotherapy followed by RT was as effective as the traditional 
approach of surgery plus radiation (Department of Veteran Affairs Laryngeal Cancer Study Group, 
1991). Subsequent research determined that RT given concurrently with chemotherapy (ChT), 
commonly referred to as chemoradiation therapy (CRT), is more effective than chemotherapy followed 
by RT (Forastiere, Koch, Trotti, & Sidransky, 2001; Forastiere et al., 2003a; Milas, Mason, Liao, & 
Ang, 2003). 
CRT has since emerged as the standard of care for HNC and is described as the best course of 
treatment for organ preservation (Forastiere et al., 2003a; Milas et al., 2003; Samant et al., 1999). The 
term “organ perseveration,” however, is arguably a misnomer since it does not necessarily mean that 
persevered organs have preserved function.  The organs may be preserved anatomically, but the toxic 
effects of RT/CRT severely damage any tissues within the radiation field.  Consequently, organs 
treated with RT/CRT rarely function normally again (Jensen, Lambertsen, & Grau, 2007; Rieger, 
Zalmanowitz, & Wolfaardt, 2006). 
Swallowing impairment (dysphagia) is one example of impaired organ function resulting from 
RT/CRT toxicity. Dysphagia is the most common side effect of RT/CRT and is recognized as one of 
the most devastating consequences of treatment (Greven et al., 2008; McColloch, Carroll, & 
Magnuson, 2010). Dysphagia secondary to RT/CRT toxicity can occur during treatment (acute), last 
for several months following RT/CRT (chronic), and can return years after initial symptom resolution 
(late; Goguen et al., 2006; Gurney, Eisele, Orloff, & Wang, 2008; Hutcheson et al., 2008; K. Jensen et 
al., 2007; Koiwai, Shikama, Sasaki, Shinoda, & Kadoya, 2010; Kotz, Costello, Li, & Posner, 2004; 
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Shiley, Hargunani, Skoner, Holland, & Wax, 2006). Radiotherapy and chemotherapy given in isolation 
contribute to their own toxic side effects.  Those side effects are compounded when radiation and 
chemotherapy are given concurrently, because chemotherapy intensifies the effects of radiation 
(Forastiere et al., 2001).  RT/CRT toxicities include but are not limited to: inflammation, reduced taste, 
xerostomia (dry mouth), oral mucositis (painful inflammation and ulceration of the mucosal lining in 
the oral and pharyngeal cavities), tissue fibrosis (scar tissue), and dental cavities (Agarwala & Sbeitan, 
2006; Gaziano, 2002; Groher & Crary, 2010).    
Severe dysphagia caused by RT/CRT toxicity frequently leads to the need for enteral nutrition 
(Cheng et al., 2006; Ishiki et al., 2012; J. Lee et al., 1998).  In fact, enteral nutrition is so common 
among patients treated with RT/CRT for HNC that many physicians now recommend feeding-tube 
placement prophylactically before beginning RT/CRT (Ishiki et al., 2012; J. Lee et al., 1998; Maurer, 
Hipp, Schafer, & Kolbl, 2011). Over 50% of patients remain dependent on a feeding tube at five 
months post RT/CRT (Greven et al., 2008; Ishiki et al., 2012), and 10% to 30% continue to be 
dependent at one year post (Ishiki et al., 2012; Paleri & Patterson, 2010).  Some patients never regain 
functional swallowing ability and end up feeding-tube dependent for the remainder of their lives 
(Hutcheson & Lewin, 2012; Maurer et al., 2011; Newman et al., 1998). 
Although most patients eventually regain oral intake sufficient to meet their nutritional needs 
and remove their feeding tubes, few regain fully normal swallowing function. Up to 82% of patients 
continue to have some level of functional deficit in swallowing at 12 months post-treatment (List et al., 
1999) and less than 50% are able to resume a normal diet (Garcie-Peris et al., 2007; Logemann et al., 
2008).  Common symptoms include difficulty eating dry foods, food sticking in the mouth or throat, 
and coughing on food or liquid secondary to penetration or aspiration (i.e., when food or liquid enters 
the airway).  As a result of these deficits, many patients have to alter their diets, eat and drink with 
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caution, and/or use compensatory swallowing strategies, all of which contribute to reduced quality of 
life (Harrison et al., 1997; Hutcheson et al., 2008; List et al., 1997; Maurer et al., 2011; Nguyen et al., 
2006).  
Speech-language pathologists (SLPs) play a primary role in assessing and treating patients with 
dysphagia as a result of to HNC (Lazarus, 2000; Murphy & Gilbert, 2009; Paleri et al., 2014; Roe et al., 
2012). The SLP’s job is to assess the patient’s swallowing function, and determine the necessity and 
course of treatment.  Ideally a thorough assessment should follow the World Health Organization 
(WHO) model and include assessment of activity limitations and participation restrictions as a result of 
the swallowing impairment (World Health Organization, 2013).  The goal of therapy is to improve or 
maintain efficient and safe oral nutritional intake, minimize the risk of aspiration pneumonia, and 
optimize quality of life. 
Historically, SLPs did not take an active role in managing dysphagia in patients with HNC until 
the patient completed cancer treatment (McColloch et al., 2010). In the 1990s, it became more common 
for SLPs to see patients prior to or during RT/CRT, with the primary purpose of educating the patient 
about side effects related to swallowing and monitoring their swallowing function (Lazarus, 2000; 
Logemann, Pauloski, Rademaker, & Colangelo, 1997; McColloch et al., 2010; Patterson & Wilson, 
2011; Pauloski et al., 2000; Roe & Ashforth, 2011).  Recent research, however, has shown a benefit of 
active prophylactic swallowing intervention prior to and during cancer treatment to minimize 
dysphagia (Carnaby-Mann, Crary, Schmalfuss, & Amdur, 2011; Carroll et al., 2008; Kulbersh, 2006; 
van der Molen et al., 2011; Virani, Kunduk, Fink, & McWhorter, 2015).  Although these studies have 
shown promising results, significant methodological differences and a lack of standardized procedures 
preclude any valid comparisons across studies.  Further, most of the studies report poor compliance to 
the exercise programs (Carnaby-Mann et al., 2011; Kotz et al., 2012; Virani et al., 2015).   
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Statement of the Problem 
The majority of patients with HNC treated with RT or CRT experience debilitating dysphagia, 
which is, in part, a direct result of the cancer treatment.  Prophylactic swallowing exercises (PSE) have 
been shown to improve functional swallowing outcomes; however, current available studies vary 
widely in treatment protocol and outcome measures (McColloch et al., 2010; Roe & Ashforth, 2011). 
Hence, a uniform best-practice protocol has not been established.  Additionally, prior PSE studies 
report poor compliance to PSE programs (Carnaby-Mann et al., 2011; Kotz et al., 2012; van der Molen 
et al., 2011; Virani et al., 2015) and anecdotal evidence suggests that swallowing pain is a main 
contributor to poor compliance (Kotz, Abraham, Beitler, Wadle, & Smith, 1999).  Although current 
available data is encouraging, many unanswered questions remain regarding the most effective and 
essential exercises, the most ideal treatment schedule and intensity, the relationship of patient variables 
to specificity of treatment (e.g., tumor location, tumor size, cancer stage, age), and how best to 
maximize patient compliance and QOL.  
Purpose 
The purpose of this study was to provide further insight into the best way to treat patients 
diagnosed with HNC suffering from dysphagia secondary to CRT toxicity.  This study specifically 
sought to determine if a PSE program consisting solely of indirect swallowing exercises (exercises that 
do not require actual swallowing; ID-PSE) is more effective and more acceptable to patients than a 
PSE program consisting of a combination of direct (exercises that require swallowing) and indirect 
swallowing exercises (C-PSE).  Previous PSE studies have included a combination of direct and 
indirect swallowing exercises. Yet, each of the previous PSE studies that mention compliance, report 
poor compliance (Carnaby-Mann et al., 2011; Kotz et al., 2012; van der Molen et al., 2011; Virani et 
al., 2015). We hypothesized that swallowing pain is the primary reason for poor compliance and that 
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swallowing pain is worsened when doing direct swallowing exercises. Based on this hypothesis, we 
also hypothesized that indirect swallowing exercises would be more comfortable for patients and, 
consequently, would result in improved compliance to PSE exercises.  Improved compliance would, in 
turn, result in better swallowing function outcomes. The following research questions and hypotheses 
guided this study. 
Research Questions and Hypotheses:  
1. In patients undergoing RT/CRT for HNC of the tongue, palate, pharynx, or larynx, is there a 
difference in compliance between patients treated with ID-PSE and similar patients treated 
with C-PSE? 
a. Null hypothesis: There will be no difference in the compliance dependent variable 
between patients completing ID-PSE and patients completing C-PSE. 
b. Alternative hypothesis:  Patients completing ID-PSE will report higher percentages on 
the exercise compliance dependent variable than patients completing C-PSE.  
2. Are oral intake outcomes different between patients undergoing RT/CRT for HNC treated 
with ID-PSE and similar patients treated with C-PSE?  
a. Null hypothesis: There will be no significant difference in the oral intake dependent 
variable (percent oral intake, FOIS, PEG-tube dependency) between the ID-PSE and 
C-PSE groups. 
b. Alternative hypothesis: The ID-PSE group will report greater scores on the oral intake 
dependent variable, as measured by percent oral intake, FOIS, and PEG-
discontinuation rate, than the C-PSE group. 
3. Are swallowing function outcomes different between patients undergoing RT/CRT for HNC 
completing ID-PSE and similar patients completing C-PSE? 
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Null hypothesis: The swallowing function dependent variable outcomes, as measured by the 
EAT-20 and the MDADI, will not differ between patients treated with ID-PSE and patients 
treated with C-PSE.  
Alternative hypothesis: The ID-PSE group will report better scores on the swallowing function 
dependent variable, as measured by the EAT-20 and MDADI, than patients treated with C-
PSE.   
4. Does a difference exist for the level of swallowing pain between patients completing ID-PSE 
and patients completing C-PSE?  
Null hypothesis: Patients treated with ID-PSE will not report different levels of the swallowing 
pain dependent variable than patients treated with C-PSE.  
Alternative hypothesis: Patients treated with ID-PSE will report lower scores on the 
swallowing pain dependent variable, as measured by a 0-5 scale, than patients treated with C-
PSE.   
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Chapter 2: Literature Review 
 Human papilloma virus (HPV) is now the primary cause of oropharyngeal head and neck 
squamous cell carcinoma (HNC; Auluck et al., 2010).  It has contributed to an exponential increase in 
incidence of HNC as well as a reduction in the average age at diagnosis (Chaturvedi et al., 2008). 
Fortunately, advances in radiotherapy (RT) and chemoradiotherapy (CRT) have contributed to 
improved survival rates and a reduced need for radical surgical dissection (Department of Veteran 
Affairs Laryngeal Cancer Study Group, 1991; Forastiere et al., 2003b). Radiotherapy and CRT, 
however, comes with significant negative side effects on swallowing function and quality of life (e.g., 
swallowing pain, dry mouth, impaired swallowing function, and reduced participation due to impaired 
swallowing function (Langmore & Krisciunas, 2010; Lazarus et al., 2000; Logemann et al., 2008).  
Recent research has focused on understanding the pathophysiological impacts on swallowing due to 
RT/CRT toxicity, how to minimize these impairments, and how best to maximize quality of life.   
Swallowing Function 
 Normal swallowing is a highly coordinated and complex process that involves over 30 muscles 
and six cranial nerves (Groher & Crary, 2010; Logemann, 1998).  Swallowing occurs in four phases: 
oral preparatory, oral, pharyngeal, and esophageal.  During the oral preparatory phase the bolus (i.e., 
food or liquid being swallowed) is prepared for swallowing. During the oral phase the bolus is 
transported from the oral cavity into the pharynx. The pharyngeal phase begins as the bolus passes the 
ramus of the mandible on its way to the pharynx, at which point the pharyngeal swallow response is 
initiated and is driven by muscular contraction and pressure. Negative pressure develops below the 
bolus as the entrance to the esophagus opens, while contraction of the pharyngeal constrictor muscles 
and the base of the tongue provide positive pressure above the bolus to drive the bolus downward. 
Simultaneously, the laryngeal valve closes, protecting the airway from aspiration. When the food 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
9 
 
passes through the upper esophageal sphincter (UES), the esophageal phase begins. This phase is also 
pressure driven and highly coordinated.  The esophageal muscles superior to the bolus contract in a 
sequential motion while the esophagus below the bolus relaxes, allowing the bolus to be propelled 
inferiorly.   
Dysphagia 
 Dysphagia is the term used to describe an impairment of swallowing.  Dysphagia can involve 
one or more of the four phases of swallowing described above and the nomenclature used to describe 
dysphagia parallels the swallowing phases (Logemann, 1998).  Oral dysphagia describes dysphagia 
isolated to impairment during the oral preparatory or oral phases. Pharyngeal dysphagia is specific to 
impairment during the pharyngeal phase.  Esophageal dysphagia describes dysphagia during the 
esophageal phase. Dysphagia most commonly involves both the oral and pharyngeal phases and is 
termed oropharyngeal dysphagia. Common symptoms of oropharyngeal dysphagia include delayed or 
prolonged mastication time, delayed or poorly coordinated transport of the bolus from the oral cavity 
into the pharynx, delayed initiation of the pharyngeal swallow response, reduced clearance of food or 
liquid through the oral or pharyngeal cavities, impaired airway closure resulting in food or liquid 
entering the airway above the vocal folds (i.e., penetration) or below the vocal folds (i.e., aspiration), 
and impaired opening of the UES. 
Interdisciplinary Approach to Dysphagia Management   
 Dysphagia is managed by a number of healthcare professionals.  Physicians manage the 
medical aspects of the disorder, which may include surgical intervention, treatment for aspiration-
related pneumonia, and pharmacological intervention for things such as pain management, treatment of 
oral infections, and treatment for a variety of esophageal disorders (e.g., gastroesophageal reflux, 
esophageal spasms) ((Groher & Crary, 2010; Murry & Carrau, 2006).  If a patient has difficulty 
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swallowing efficiently, or cannot swallow safely and requires enteral nutrition, it is the job of the 
dietician to make appropriate diet recommendations in order for the patient to meet his/her nutritional 
needs (Groher & Crary, 2010; Logemann, 1998).  Dieticians and physicians work closely with speech-
language pathologists (SLPs), whose role is to assess oropharyngeal swallowing function, make 
recommendations related to swallowing safety, and provide behavioral treatment as appropriate. 
Behavioral treatment, consisting of diet modifications, swallowing exercises, and/or swallowing 
strategies, is the most common form of management of oropharyngeal dysphagia (Groher & Crary, 
2010; Logemann, 1998; Murry & Carrau, 2006). 
Swallowing Assessment    
Three primary assessment tools are used to assess oropharyngeal swallowing function: clinical 
(or bedside) swallowing evaluation, modified barium swallow study (MBS), and fiberoptic endoscopic 
evaluation of swallowing (FEES; Groher & Crary, 2010; Logemann, 1997).  A clinical swallow 
evaluation includes a detailed case history of subjective complaints, current and past medical status and 
treatment, an oral mechanism examination, and physical examination during swallowing trials. The 
purpose of the clinical swallow evaluation is to determine the patient’s ability to prepare and move the 
bolus from the oral cavity to the pharynx, assess coordination of swallow response timing, subjectively 
assess hyolaryngeal elevation and excursion with palpation, and look for signs or symptoms of 
aspiration (Gaziano, 2002; Lazarus, 2000; Patterson & Wilson, 2011).  The clinical swallow evaluation 
is a valuable assessment tool but is limited in that it cannot objectively determine the presence and 
severity of aspiration, the amount and location of pharyngeal residue, or the exact physiological 
impairment contributing to these symptoms (Groher & Crary, 2010).  A MBS or FEES, which provide 
video imaging of the swallow in real time, is often necessary because of these limitations.    
A modified barium swallow (MBS) study is a radiological examination performed under 
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videoflouroscopy in a radiology suite (Logemann, 1997).  Videoflouroscopy allows visualization of the 
oral, pharyngeal, and upper esophageal phases of swallowing while the patient ingests food and liquid 
mixed with barium.  An SLP directs the exam, typically with the assistance of a radiologist.  The SLP 
administers various consistencies of food and liquid to the patient while observing the patient’s 
swallowing function under fluoroscopy (i.e., continuous x-ray imaging). The SLP assesses safety and 
tolerance of each type of texture and trials compensatory swallowing strategies as appropriate, if the 
patient presents with a functional swallowing impairment. 
A fiberoptic endoscopic evaluation of swallowing (FEES) is an endoscopic exam whereby a 
flexible fiberoptic endoscope is passed transnasally to the level of the soft palate for a superior view of 
the pharynx and larynx while the patient ingests food and liquid.  Reliability studies comparing FEES 
to MBS have shown FEES to be a reliable measure in regards to pharyngeal and laryngeal function 
(Colodny, 2002; Leder, Sasaki, & Burrell, 1998; Schatz, Langmore, & Olson, 1991); however, a FEES 
does not allow visualization of the oral cavity or esophagus, which is a significant disadvantage in the 
case of head and neck cancer patients who often present with deficits in these areas (Pauloski, 2008).  
For this reason, MBS is the more commonly used instrumental exam.  The goal of either exam is to 
determine whether or not a patient is safe for per oral (P.O.) nutrition, the exact nature of the 
swallowing impairment, the safest and least restrictive diet for the patient, the usefulness of swallowing 
compensatory strategies, and what physiological impairments should be targeted in treatment (Agarwal 
et al., 2011; Bleier et al., 2007; Lazarus, 2000; Logemann, 1997; Patterson & Wilson, 2011; Pauloski, 
2008).      
Swallowing Treatment  
Behavioral treatment options for oropharyngeal dysphagia fall into two broad categories -- 
compensatory swallowing strategies (i.e., postural modifications, bolus size and consistency 
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modifications, swallowing maneuvers) and restorative swallowing exercises (i.e., active exercises to 
improve range of motion (ROM), coordination, and/or strength of oral, pharyngeal, or laryngeal 
structures) (Pauloski, 2008; Robbins et al., 2008).  Compensatory strategies improve swallowing 
function while the strategies are performed but do not result in long-term physiological improvement; 
hence, the patient only benefits from compensatory strategies when he/she is actively using the 
strategies (Loeb, Becker, Eady, & Walker-Dilks, 2003; Pauloski, 2008). Restorative therapy, on the 
other hand, is intended to improve swallowing physiology to minimize or eliminate swallowing 
impairment (Pauloski, 2008; Robbins et al., 2008).  
Restorative therapy is most appropriate for prophylactic intervention for patients with HNC 
treated with RT/CRT because of its goal to minimize physiological impairment. The primary 
overarching pathophysiological cause of dysphagia in patients with HNC treated with RT/CRT is 
reduced range of motion secondary to edema and tissue fibrosis (Tang et al., 2011) and muscle 
weakness, secondary to disuse atrophy (Langmore & Krisciunas, 2010). Restorative therapy in these 
patients should, therefore, target range of motion and strengthening of swallowing structures. 
Range of motion (ROM) exercises.  Range of motion exercises for the jaw, tongue, and 
larynx are designed to stretch and move the structures in all directions in order to improve or maintain 
ROM and flexibility, which is necessary for functional swallowing as well as speech.  While research 
has not clearly defined an optimal exercise schedule and intensity, five to 10 repetitions of each 
exercise per session and a goal of five to 10 sessions per day is generally recommended (Logemann, 
1998; Pauloski, 2008). Logeman et al. (1997) provided pilot data showing that HNC patients who 
completed jaw, tongue, and laryngeal ROM exercises following RT exhibited significantly better 
speech and swallowing function than those who did not complete ROM exercises.    
Jaw ROM exercises.  Restricted jaw opening as a result of radiation fibrosis following RT or 
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CRT is termed trismus.  Current treatment options for jaw ROM include passive stretch exercises such 
as finger-assisted mouth opening, stacked tongue depressors, and use of the Therabite device (a device 
inserted in the mouth that passively stretches the mouth aperture by the patient squeezing a lever) 
(Buchbinder, Currivan, Kaplan, & Urken, 1993; Dijkstra, Sterken, Pater, Spijkervet, & Roodenburg, 
2007; Tang et al., 2011). The patient may also actively stretch by simply opening the mouth as wide as 
possible and holding the stretch for two seconds.  The patient is also instructed to move the jaw side to 
side in the same fashion (Logemann et al., 1997; Tang et al., 2011). Several studies have shown the 
benefits of these exercises for relieving trismus (Buchbinder et al., 1993; Cohen, Deschler, Walsh, & 
Hayden, 2005; Tang et al., 2011). 
Tongue ROM exercises. Tongue ROM can also be limited due to the effects of radiation 
fibrosis following RT or CRT.  Tongue ROM exercises are done actively.  The patient is instructed to 
move the tongue forward and back, side to side, and in a circle (Logemann et al., 1997). Elevation of 
the back of the tongue can be targeted by the patient placing the tongue in the position for producing 
the /k/ or /g/ sound.  This stretch can be increased by the patient holding the tongue in the /k/ position 
and then opening the jaw as far as possible (Logemann, 1998).   
Laryngeal ROM exercises. Laryngeal elevation and excursion (upward and forward movement 
of the laryngeal complex) is important for airway closure and epiglottic inversion, both of which are 
important for moving the bolus through the pharynx, without residue left behind and without aspiration 
(Logemann, 1998). Reduced laryngeal elevation/excursion is correlated with limited oral intake and 
diet in HNC patients within the first year following treatment (Pauloski et al., 2006).  Three exercises 
are designed to target laryngeal elevation and excursion, including effortful pitch glide, Mendelsohn 
maneuver, and the Shaker exercise. 
Effortful pitch glide.  The effortful pitch glide, also termed the pharyngeal squeeze (Fuller, 
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Leonard, Aminpour, & Belafsky, 2009) and falsetto voice (Pauloski, 2008), involves gliding the voice 
up the pitch scale and then sustaining a high-pitched voice as long as possible.  The rationale for the 
exercise is that during high-pitched voice production the larynx elevates and the pharyngeal 
constrictors contract to a similar extent as during swallowing (Fuller et al., 2009; Miloro, Langmore, & 
Pearson Jr, 2014).   
Mendelsohn maneuver.  The Mendelsohn maneuver is an intentional prolongation of laryngeal 
elevation at the height of the swallow.  The maneuver has been shown to improve the extent of 
laryngeal elevation as well as upper esophageal sphincter opening, both of which are commonly 
impaired in HNC patients treated with RT or CRT (Kahrilas, Logemann, Krugler, & Flanagan, 1991; 
Lazarus, Logemann, & Gibbons, 1993). 
The Shaker exercise.  The shaker exercise is an isometric/isokinetic exercise designed to 
improve UES opening and laryngeal elevation by contracting the suprahyoid muscles responsible for 
laryngeal elevation/excursion (Shaker et al., 1997).  Since both laryngeal elevation/excursion and 
reduced UES opening are common following RT/CRT for HNC, there is a strong rationale for using 
this exercise with this population.  
The Shaker exercise is done with the patient in a supine position.  During the isometric portion 
of the exercise, the patient lifts the head so that the chin approaches the chest.  This position is held for 
one minute, followed by a one-minute rest.  During the isokinetic portion of the exercise, the patient 
lifts and lowers the head 30 times, with a hold time of only two to three seconds at the top.  Strong 
evidence exists for the efficacy of this exercise for improving anterior laryngeal movement and UES 
opening (Easterling, Grande, Kern, Sears, & Shaker, 2005; Shaker et al., 2002).  
Oral and pharyngeal strengthening exercises. Reduced strength of the tongue and 
pharyngeal constrictors is well documented in patients with HNC treated with RT/CRT (Eisbruch et 
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al., 2002; Kotz et al., 1999; Kotz et al., 2004; Smith, Kotz, Beitler, & Wadler, 2000). The following 
exercises are commonly prescribed for improving tongue and pharyngeal constrictor strength.  
General tongue strengthening.  Tongue strength is typically targeted by pressing the tongue 
against a wooden tongue depressor, or something similar, to provide resistance.  The tongue can be 
pressed straight out, to the right and left, and up and down.  Lateral tongue strength also can be targeted 
by pressing the tongue against each cheek (Logemann, 1998). Tongue resistance exercises have been 
shown to be effective in healthy individuals as well as stroke patients (Clark, O'Brien, Calleja, & 
Corrie, 2009; Robbins et al., 2005; Robbins et al., 2007), but to date only one study has been published 
on tongue strengthening exercises in patients with HNC treated with RT/CRT (Lazarus et al., 2014). 
Lazarus and colleagues compared tongue-strengthening exercises paired with traditional swallowing 
exercise to traditional swallowing exercises alone in patients post-RT/CRT treatment for HNC. They 
found no statistically significant differences between the two groups on measures of tongue strength or 
swallowing function. The authors postulated that poor compliance to the program may have 
contributed to the findings.  
Tongue base retraction strengthening.  Tongue-base retraction refers to movement of the 
posterior tongue towards the posterior pharyngeal wall.  Tongue base retraction is essential during 
swallowing to assist in pressing food or liquid through the pharynx into the esophagus (Logemann, 
1998). Impaired tongue-base retraction is one of the most common physiological impairments 
following RT/CRT for HNC (Eisbruch et al., 2002; Lazarus, 2000; Lazarus et al., 2007). Common 
exercises for strengthening tongue-base retraction include: repetitive pulling of the tongue as far back 
as possible into the oral cavity (i.e., the tongue pull-back; (Veis, Logemann, & Colangelo, 2000), 
gargling (Johnson, Herring, & Daniels, 2014; Veis et al., 2000), yawning (Johnson et al., 2014; Veis et 
al., 2000), the effortful swallow (Hind, Nicosia, Roecker, Carnes, & Robbins, 2001; Huckabee, Butler, 
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Barclay, & Jit, 2005; Huckabee & Steele, 2006; Lazarus et al., 1993; Pouderoux & Kahrilas, 1995), 
and the Masako maneuver (Fujiu & Logemann, 1996). The gargle task has proven to be more effective 
than the tongue pull-back and pretending to yawn (Veis et al., 2000). The effortful swallow and 
Masako are described separately below.  
The effortful swallow. The effortful swallow is a strengthening exercise whereby the patient 
squeezes all of the muscles used for swallowing as strongly as possible during the swallow.  The 
patient is instructed to pay attention to pushing the tongue up against the palate (Huckabee & Steele, 
2006). The effortful swallow is often prescribed as a compensatory strategy as it has been shown to 
reduce pharyngeal residue after the swallow by improving movement of the bolus through the pharynx 
(Hind et al., 2001; Huckabee et al., 2005; Huckabee & Steele, 2006). Biomechanically, the effortful 
swallow results in increased oral and pharyngeal pressure, prolonged laryngeal closure, increased 
hyolaryngeal elevation and excursion, and prolonged distention of the UES (Hind et al., 2001; Hiss & 
Huckabee, 2005; Lever et al., 2007). In this regard, the effortful swallow can be prescribed for 
improving tongue-base retraction, hyolaryngeal elevation and excursion, pharyngeal contraction, and 
UES opening. A number of studies have shown the effortful swallow to be effective in HNC patients 
treated with RT/CRT (Carnaby-Mann & Crary, 2010; Crary, Carnaby, LaGorio, & Carvajal, 2012; 
Lazarus, Logemann, Wook Song, Rademaker, & Kahrilas, 2002). 
The Masako maneuver. The Masako, or tongue-hold, maneuver is performed by swallowing 
while the tongue is anchored between the front teeth.  This exercise has been shown to improve tongue-
base retraction and pharyngeal contraction (Fujiu & Logemann, 1996). Lazarus and colleagues (2002) 
provided evidence that this exercise improved pressure and duration of contact between the tongue-
base and posterior pharyngeal wall during the swallow in patients with HNC treated with RT.   
Numerous restorative swallowing exercises have been designed and validated to improve 
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swallowing physiology. However, designing the most appropriate prophylactic swallowing exercise 
protocol specifically for patients with HNC treated with RT or CRT requires an understanding of 
RT/CRT and the associated toxicity that contributes to dysphagia.  
The Interaction between Radiation Therapy and Chemotherapy 
To understand how RT/CRT toxicity impact swallowing function, it is helpful to review how 
RT works and how chemotherapy (ChT) interacts with RT during CRT. There are two forms of RT – 
external beam and internal.  External beam radiation is delivered from outside the body by aiming a 
beam(s) of radiation to the location of the cancer, while internal radiation is delivered internally by 
placing radioactive sources directly into a cancer site (Baskar, Lee, Yeo, & Yeoh, 2012). External 
beam radiation is the most common approach used to treat HNC (Baskar et al., 2012).  Regardless of 
the delivery method, radiation therapy works primarily by damaging the DNA of cells, thereby 
reducing their ability to divide and proliferate (Baskar et al., 2012).  
Multiple complex cellular mechanisms are involved during radiation-induced cellular DNA 
damage, but two common types of damage are single-strand breaks and double strand breaks (Seiwert, 
Salama, & Vokes, 2007a). Double strand breaks (DSBs) involve breaking of both strands of the DNA 
double helix. This type of break is irreparable and leads to certain cellular death; however, DSBs are 
not easily achieved. Single strand breaks (SSBs), on the other hand, involve just one strand of the DNA 
double helix. SSBs are relatively easy to achieve, but they are not likely to lead to cellular death 
because the breaks are easily repaired through cellular repair mechanisms (Baskar et al., 2012; Seiwert 
et al., 2007a). It is, in part, because of these repair mechanisms that chemotherapy added adjunctively 
to RT (as in CRT) is more effective that non-synchronous RT and chemotherapy.  Chemotherapy 
(ChT) drugs are believed to interfere with damaged cells’ ability to repair themselves, thereby 
increasing the rate of cell death. In this way, ChT is said to act as a radio-sensitizing agent (Baskar et 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
18 
 
al., 2012; Seiwert et al., 2007a; G. Wilson, Bentzen, & Harari, 2006). 
The most common ChT drug given to patients with HNC during CRT is Cisplatin (Seiwert et 
al., 2007a; Seiwert, Salama, & Vokes, 2007b). In addition to Cisplatin interfering with cellular repair 
mechanisms to increase cellular death following RT-induced DNA damage, Cisplatin also interacts 
with nucleophilic sites on DNA and RNA, which distorts the DNA structure and interferes with 
nucleotide replication and transcription (Seiwert et al., 2007b).  
Unfortunately, the cellular damage caused by RT/CRT effects normal cells as well as cancer 
cells. The primary outcome goal of RT/CRT, therefore, is to: (1) maximize radiation and cellular death 
in cancer cells, while (2) minimizing radiation exposure and cellular death in normal cells. Delivering 
RT in fractions and advances in delivery and imaging techniques have helped improve these outcomes.   
Fractionation. Radiation therapy is generally delivered in fractions, which consists of several 
small doses of radiation rather than less frequent larger doses (Baskar et al., 2012). The purpose of a 
fractionated RT schedule is to enhance the survival of normal cells over cancer cells. This is explained 
by the differences in radiobiological properties of cancer cells and normal cells. Normal cells tend to 
divide and proliferate more slowly than cancer cells; whereas, cancer cells tend to divide and 
proliferate rapidly. By delivering RT in smaller, sublethal doses, normal cells have a chance to repair 
themselves before replicating. However, cancer cells are likely to replicate themselves before DNA 
damage has been repaired (Baskar et al., 2012). The typical RT schedule for patients with HNC is 35 
fractions of 1.8 to 2 Gy of radiation per fraction, delivered five days per week (Mallick & Waldron, 
2009).   
Intensity modulated radiation therapy. Intensity modulated radiation therapy (IMRT) is the 
current standard radiation delivery method for patients with HNC (Lee & Terezakis, 2008). IMRT is an 
advanced method of delivering radiation three-dimensionally using multiple radiation beams to 
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maximize radiation dose to the intended target with a sharp radiation gradient at the planned margin to 
minimize the dose to normal tissue. The radiation oncologist uses imaging studies to outline the target 
area. This information, as well as the desired radiation dose, is analyzed by a computer-optimized 
algorithm, which determines the most likely treatment plan that maximizes radiation to the target area, 
while minimizing radiation to the surrounding normal tissue. IMRT has been shown to reduce 
xerostomia and preserve other anatomical structures relative to traditional RT (Eisbruch, 2005). 
 Image-guided radiotherapy. As treatment margins have increasingly tightened to spare 
normal adjacent tissue, so has the necessity to increase accuracy of each RT dose.  Image-guided 
radiotherapy (IGRT) has been born out of this necessity (Baskar et al., 2012). Tightening treatment 
margins comes with an increased risk of missing cancerous tissue at or near the margin of the radiation 
field. Additionally, slight positional errors from one RT session to the next may result in missing small 
portions of cancerous tissue in one area while increasing unintentional exposure to critical structures in 
another area. IGRT uses pre-radiation imaging to detect and correct for such errors before each RT 
session. Head and neck and prostate tumors are two common sites that benefit from IGRT (Baskar et 
al., 2012).  
 Despite these advances, patients with HNC treated with RT or CRT continue to suffer from 
significant negative side effects due to RT/CRT toxicity. These side effects contribute to dysphagia in 
nearly all patients during treatment and up to 64% of patients post-treatment (Francis, Weymuller, 
Parvathaneni, Merati, & Yueh, 2010; Hutcheson & Lewin, 2012).    
RT/CRT Toxicity-Induced Dysphagia      
Mucositis, xerostomia, and reduced taste are the most common acute side effects caused by 
RT/CRT toxicity that impact swallowing. Mucositis results in inflammation and ulceration of the 
mucosal lining in the oral and pharyngeal cavities and contributes to severe oral and throat pain 
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(Rodriguez-Caballero et al., 2011). This pain contributes to severe odynophagia (i.e., painful 
swallowing). Mucositis typically begins within two to three weeks of the onset of RT/CRT, gets 
progressively worse throughout, and then gradually declines over a matter of weeks to months 
following completion of RT/CRT.  It is not uncommon for the pain to become significant enough to 
require narcotic analgesics (e.g., morphine; Agarwala & Sbeitan, 2006; Elting et al., 2008). Xerostomia 
typically begins within a few weeks of beginning RT/CRT and also gets progressively worse (de 
Castro Jr. & Honda Federico, 2006). Dry mouth contributes to thick saliva that, for many patients, 
causes gagging.  Xerostomia improves somewhat following RT/CRT but a majority of patients suffer 
to some extent from chronic dry mouth for the rest of their lives (Braam et al., 2005; Büntzel, Glatzel, 
Mücke, Micke, & Bruns, 2007; de Castro Jr. & Honda Federico, 2006; S. B. Jensen et al., 2010). 
Reduced taste also begins during RT/CRT and usually resolves within several months following 
completion of treatment (Vissink, Jansma, Spijkervet, Burlage, & Coppes, 2003). Mucositis, 
xerostomia, and reduced taste cumulatively result in avoidance of oral feeding (some patients avoid 
swallowing all together) at some point during RT/CRT.  Lack of swallowing then contributes to disuse 
atrophy of the swallowing muscles (Franzmann, Lundy, Abitbol, & Goodwin, 2006), which further 
contributes to dysphagia. These side effects resolve significantly within a few weeks following the last 
RT/CRT (Elting et al., 2008); however, return of normal and safe swallowing function takes much 
longer as a result of the time required for the swallowing muscles to regain functional strength (Frowen 
& Perry, 2006).        
The primary late side effect of RT/CRT that contributes to dysphagia is radiation-induced 
fibrosis (Delanian & Lefaix, 2007; O'Sullivan & Levin, 2003; Stubblefield, 2011). Fibrosis is scar 
tissue of the connective tissue that was exposed to radiation and is less common than mucositis and 
xerostomia.  In simplistic terms, it is caused by dysregulation of aspects of wound healing including 
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up-regulation of transforming growth factor β1, a peptide involved in collagen production (Bleier et al., 
2007; Delanian & Lefaix, 2004). Fibrosis contributes to hardening of connective tissue, which impacts 
flexibility and range of motion, which is essential for functional swallowing. Fibrosis is generally 
considered irreversible, but some studies have shown improvements with antioxidant therapy, anti-
inflammatory treatment, and vascular treatment (Delanian & Lefaix, 2004; Delanian & Lefaix, 2007).       
RT/CRT toxicities cumulatively contribute to the following biomechanical and 
pathophysiological impairments that contribute to dysphagia: reduced tongue-base retraction, reduced 
tongue control, delayed swallow initiation timing, weak pharyngeal contraction, reduced epiglottic 
inversion, reduced laryngeal excursion, poor closure of the laryngeal vestibule, and reduced or 
shortened opening of the UES (Chang et al., 2003; Frowen & Perry, 2006; Hutcheson et al., 2008; Kotz 
et al., 2004; Logemann et al., 2008; Smith et al., 2000). These impairments contribute to difficulty 
transporting food from the mouth to the pharynx, premature spillage of food into the pharynx, difficulty 
getting food through the pharynx into the esophagus, and aspiration that is often silent (Hutcheson & 
Lewin, 2012; Nguyen et al., 2009; Nguyen et al., 2006).  
 The grueling nature of RT/CRT therapy also has a significant negative impact on QOL (de 
Graeff et al., 1999; El-Deiry, Futran, McDowell, Weymuller Jr, & Yueh, 2009; List et al., 1997; 
Ringash et al., 2008; Rogers, Ahad, & Murphy, 2007) and studies show unequivocally that swallowing 
function is directly correlated with QOL (Garcie-Peris et al., 2007; Hammerlid, Silander, Hörnestam, & 
Sullivan, 2001; Harrison et al., 1997; Maurer et al., 2011; Oates et al., 2007). This is not surprising 
given the strong cultural emphasis on eating and drinking at social gatherings. This association speaks 
to the importance of following the World Health Organization (WHO) model, which dictates 
consideration of activity limitations and participation restrictions when creating the most optimal 
prophylactic swallowing intervention protocol (World Health Organization, 2013).  
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Quality of Life During and Following RT/CRT for HNC 
 A vast literature base exists on QOL in patients with HNC. Rogers et al.(2007) conducted a 
structured review and theme analysis of papers on QOL over a 10-year span and found a total of 165 
papers with a range of 18 to 34 publications per year.  Over 50 QOL instruments were used across the 
papers, the majority of them validated. The sheer vastness of papers and QOL instruments designed 
specifically for patients with HNC attests to the importance of the topic. This review will highlight 
some of the most common instruments used to assess QOL in patients with HNC, including the 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 
(EORTC QLQ-C30) and the EORTC QLQ-Head and Neck Caner module (QLQ-H&N35), the 
Performance Status Scale for Head and Neck Cancer Patients (PSS-HN), the Functional Assessment of 
Cancer Therapy-Head and Neck (FACT-H&N), and the MD Anderson Dysphagia Inventory 
(MDADI).  
 The EORTC QLQ-C30 is in its 3rd version.  It is a patient-based survey instrument for 
assessing health-related QOL of cancer patients, and consists of a global scale as well as five functional 
subscales: physical, role, emotional, cognitive, and social.  The EORTC QLQ-Head and Neck Cancer 
module (QLQ-H&N35) is a supplementary module specific to head and neck cancer.  This module 
consists of six symptom scales (pain, swallowing, taste/smell, speech, social eating, and social 
contacts) and seven single items (sexuality, teeth problems, problems opening mouth, dry mouth, 
sticky saliva, cough, and feeling ill). Both the EORTC QLQ-C30 and the QLQ-H&N35 modules have 
been vetted for validity and reliability specific to the HNC patient population. Reliability scores range 
from .72 to .87 and construct validity correlations are in the acceptable range with other valid 
instruments (Arraras et al., 2002; Bjordal & Kaasa, 1992; Bjordal et al., 1999; Bjordal et al., 2000; 
Chie, Hong, Lai, Ting, & Hsu, 2003; Osoba, Aaronson, Zee, Sprangers, & Velde, 1997). 
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 The PSS-HN is a clinician-rated QOL instrument with three subscales: normalcy of diet, 
understandability of speech, and eating in public. Each subscale is scored from 0 to 100 with better 
performance indicated by higher scores. Original validation data indicated reliability scores of .84 for 
Normalcy of Diet, .43 for Understandability of Speech, and .81 for Eating in Public. The scale was 
found to have sufficient validity for discriminating HNC from other types of cancer (List et al., 1996; 
List, Ritter-Sterr, & Lansky, 1990).   
 The MDADI, developed by Chen and colleagues (2001), is a self-administered, Likert-scale 
questionnaire designed and validated specifically for evaluating the impact of dysphagia on QOL in 
patients treated for HNC.  This measure consists of 20 items and includes global, emotional, functional, 
and physical subscales. Each question is scored from 1 to 5 with 5 indicating the best QOL.  The mean 
of each subscale is multiplied by 20 to obtain a score between 0 (extremely low functioning) and 100 
(high functioning). Original validation and reliability research was completed by Chen et al.(2001) who 
validated the MDADI against the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) 
on 100 HNC patients. Reliability coefficients for the MDADI subscales ranged from .85 to .93. Test-
retest reliability of the subscales ranged from .69 to .88.  
 The FACT-H&N was originally developed by Dr. David Cella and colleagues in 1993 and is 
now in its 4th version (Webster, Cella, & Yost, 2003). It is a self-report instrument that consists of a 
core questionnaire called the FACT-G, and a disease-specific subscale for HNC patients. The FACT-G 
consists of 28 general QOL items and HNC subscale consists of 11 QOL items. Each item is rated on a 
0 to 4 Likert-type scale with a higher score indicating better QOL. Items are combined to indicate 
functioning in six areas: physical well-being, social and family well-being, relationship with doctor, 
emotional well-being, functional well-being, and head and neck related symptoms. The FACT-H&N 
has been tested mainly as a discriminative measure. It has met the minimum acceptable reliability 
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requirements (>.70; List et al., 1996) and construct validity has been demonstrated in two studies 
(D'Antonio, Zimmerman, Cella, & Long, 1996; List et al., 1997). 
 Maurer (2011) used the EORTC QLQ-C30 and the EORTC H&N 35 to assess QOL before 
treatment, end of treatment, and six and 12 months post-treatment in 35 patients with HNSCC treated 
with RT or CRT.  At the beginning of therapy, dysphagia caused by surgery or the tumor itself did not 
influence global QOL scores. However, at the end of treatment, the severity of dysphagia was highly 
correlated with a decline in global QOL score (p = .03, r = -.321).  This correlation was maintained at 
six and 12 months post-treatment.   
One of the largest QOL studies on this population was conducted by Hammerlid et al. (2001). 
They followed 232 patients with HNC.  Over 90% of the patients were treated with RT or CRT.  The 
patients were followed throughout treatment and for three years following treatment. QOL was 
measured with the EORTC QLQ-30 and QLQ H&N35.  All but two of the single item scores 
deteriorated significantly between baseline and three months after treatment onset.  The largest changes 
were found for senses, dry mouth, role function, loss of appetite, fatigue, overall pain, pain specific to 
oral and pharyngeal structures, swallowing, and social eating.  At six months, all QOL domain and 
single item scores had improved except for problems with dry mouth and teeth.  At a three-year follow-
up, 13 of the single item scores had deteriorated further with the largest deteriorations in dry mouth, 
senses, and teeth.  A logistic regression analysis indicated that in regards to emotional functioning, pain 
was the only predictor of global QOL and emotional functioning and swallowing pain predicted the 
degree of pain.    
 List et al.(1999) used the Functional Assessment of Cancer Therapy-Head and Neck (FACT-
H&N) and the Performance Status Scale for Head and Neck Cancer Patients (PSS-HN) to assess QOL 
in 64 HNC patients treated with CRT at baseline, acutely (towards the end of CRT), and at three-month 
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intervals following CRT.  During the acute phase, a substantial decline was observed across most areas 
of QOL with the most significant decreases in global performance status and normalcy of diet on the 
PSS-HN, and physical, functional, and overall well-being on the FACT-H&N. Post-treatment data 
showed a gradual improvement in QOL, with many, but not all, subscales reaching baseline status. The 
most common complaints at 12 months post CRT were swallowing, hoarseness, and mouth pain.  
 Wilson (2011) used the MD Anderson Dysphagia Inventory (MDADI) to assess QOL on 167 
HNC patients treated with CRT. They administered the MDADI before treatment and at three, six, and 
12 months after treatment. On average, QOL scores declined by 18% from baseline to three months 
post-treatment and there was minimal improvement in QOL scores for the group as a whole between 
three months and 12 months post-treatment. The strongest predictor of QOL scores at 12 months was 
total radiation dose, with patients receiving 50 Gy or less having the best outcomes.      
In summary, an extensive literature base demonstrates chronically reduced QOL in patients 
treated for HNC and dysphagia is a primary contributor to reduced QOL. Additionally, Hammerlid et 
al. (2001) found that swallowing pain was a predictor of global QOL.  Any dysphagia intervention 
model for patients suffering from RT/CRT-toxicity-induced dysphagia should, therefore, consider 
QOL, specifically swallowing-related pain.  
Treatment Models for Management of RT/CRT-Toxicity-Induced Dysphagia  
The Reactive Model. The traditional model for dysphagia management in patients with HNC 
treated with RT/CRT is reactive in nature.  In this model patients are referred for swallowing treatment 
only if his/her dysphagia does not resolve after a recovery period following RT/CRT (McColloch et al., 
2010).  The primary criticism of this model is that these patients do not receive adequate education and 
counseling regarding swallowing-related side effects during RT/CRT, the likely rehabilitation needs 
following RT/CRT due to dysphagia, and they are given minimal education in dysphagia symptoms to 
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watch for or how to compensate for those symptoms. Patients’ understanding of what is to come and 
their responsibility in the recovery process enhances the prognosis for ultimate successful rehabilitation 
(Logemann et al., 1997). Consequently, an educational/monitoring model has emerged that involves a 
much earlier referral to speech-language pathology. 
The Educational/Monitoring Model. In the 1990s many physicians began adhering to an 
educational/monitoring model. This model dictates referral to an SLP prior to RT/CRT treatment with 
the purpose of obtaining baseline swallowing function, educating the patient about swallowing-related 
side-effects of RT/CRT, and monitoring swallowing safety throughout treatment to maximize safety of 
nutritional intake and to determine if and when the patient needs a feeding tube (Lazarus, 2000; 
Logemann et al., 1997; McColloch et al., 2010; Patterson & Wilson, 2011; Pauloski et al., 2000; Roe et 
al., 2012). Although this model is favored over the reactive model (Logemann et al., 1997; Patterson & 
Wilson, 2011) it is still a passive approach to dysphagia management and does nothing to minimize or 
prevent RT/CRT-induced dysphagia.  Inherently, a model that prevents or minimizes dysphagia would 
be superior to both the reactive and educational/monitoring models.   
The Prophylactic Model. Recent research has revealed the benefits of a proactive intervention 
model that employs active swallowing exercises prior to and during RT/CRT with the goal of 
minimizing RT/CRT-induced dysphagia.  To date, seven published studies have demonstrated a benefit 
of prophylactic swallowing exercises (PSE) in patients with HNC treated with RT or CRT (Ahlberg et 
al., 2011; Carnaby-Mann et al., 2011; Carroll et al., 2008; Kotz et al., 2012; Kulbersh, 2006; van der 
Molen et al., 2011; Virani et al., 2015) and one study has shown no benefit of prophylactic intervention 
(Ahlberg et al., 2011).  Overall, research shows promise towards validating prophylactic intervention; 
however, relatively few studies have been completed and those that have been completed vary 
markedly in methodology and do not include effect sizes, preventing cross-study comparison.  
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Additionally, compliance to PSE programs has been poor; yet, only one PSE study considered 
compliance when designing the PSE program (Virani et al., 2015).  A summary of each of the prior 
PSE studies can be viewed in Table 1.  
Carroll et al. (2008) conducted the first randomized control trial investigating prophylactic 
dysphagia intervention for patients with HNC treated with RT or CRT. Eighteen participants treated 
with CRT for HNC were included in the study. Nine control participants received reactive swallowing 
therapy following CRT (if needed) and nine experimental participants received prophylactic 
swallowing exercises (PSE) that began two weeks prior to CRT. The exercises included tongue 
resistance, Masako, effortful swallow, Mendelsohn maneuver, and Shaker exercise. All exercises were 
performed with 10 repetitions, five times per day except the Shaker, which consisted of three, one-
minute holds, and 30 repetitions (the authors did not specify how many times per day the Shaker was 
prescribed). Outcome measures for the study included a modified barium swallow study (MBS) three 
months post-CRT. The MBS measured hyoid movement, tongue-base retraction, epiglottic inversion, 
opening of the upper esophageal sphincter, and the penetration-aspiration scale (PAS; validated by 
Rosenbek, Robbins, Roecker, Coyle, & Wood, 1996). Significant differences were found between the 
two groups in tongue-base retraction and epiglottic inversion.  Specifically, the experimental group had 
better tongue-base retraction and epiglottic inversion than the control group; in fact, six of the nine 
patients in the control group had no epiglottic inversion, whereas only one patient in the exercise group 
had no inversion.  The groups did not differ in regards to PEG tube removal time, which the 
researchers suspected was a result of sample size.  
The primary weaknesses of Carroll et al. (2008) include the following: (1) none of the 
measurements used indicated functional deficits in swallowing; (2) outcome measures were only taken 
at three months post-CRT, which may have missed differences that occurred earlier or later in the post-
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CRT phase, (3) they did not include a measure of QOL, and (4) they did not report on compliance to 
the PSE program. 
Kotz et al. (2012) also conducted a randomized controlled trial comparing a PSE program to a 
reactive dysphagia intervention program.  The experimental group (n = 13) received PSE that began at 
the beginning of RT/CRT and continued through RT/CRT.  The control group (n = 13) was offered 
dysphagia treatment if the patient had dysphagia symptoms after completion of RT/CRT.  All but one 
patient was treated with CRT for a newly diagnosed HNC.  One patient was treated with RT alone.  
Patients were excluded if surgery was a part of their cancer treatment, if they had a tracheostomy, if 
they had undergone previous RT, or if they had a neurologic disease that could impact swallowing 
function.  Prophylactic exercises consisted of: effortful swallow, Masako, tongue base retraction, the 
super-supraglottic swallow technique, and the Mendelsohn maneuver.  The patients were instructed to 
complete three sets of 10 repetitions of each exercise daily and to vary the order of the exercises. 
Assessments included the Performance Status Scale for Head and Neck Cancer patients (PSS-H&N) 
and the Functional Oral Intake Scale (FOIS), as well as PEG removal time post-RT/CRT (for patients 
who required a PEG).  The participants were assessed at baseline, within one week of the completion 
of RT/CRT, and at three months, six months, nine months, and 12 months post-RT/CRT.  Results of 
the PSS-H&N and FOIS followed similar patterns; no significant differences between the groups 
existed at treatment-end, or at nine months or 12 months post-CRT.  The experimental group was 
significantly better than the control group at three months and six months post-CRT for both the PSS-
H&N and the FOIS, indicating a faster recovery in the experimental group. Twelve of the patients 
required PEG tubes.  PEG-removal time was on average three months post-CRT and there was no 
significant difference between the two groups (p = .15), which is not surprising given the small group 
sizes. Kotz et al. also reported that 69% of the intervention patients were unable to continue the 
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exercises throughout the entire course of CRT.  Approximately half of the participants quit the 
exercises after four weeks and the other half quit after five weeks.   
Several strengths and weaknesses of Kotz et al. (2012) inform the current study.  The data 
collection schedule Kotz et al. used adequately captured group differences within one year of RT/CRT. 
Significant differences were found at three and six months post RT/CRT but not before or after three 
and six months, indicating that the most optimal time to capture short-term differences is within the 
first six months post RT/CRT. The primary weakness of Kotz et al.’s PSE program was the poor 
compliance to the program.  Kotz et al. reported that poor compliance was not specifically due to an 
effect of the prophylactic exercises, but was rather due to oral and throat pain as well as general fatigue. 
However, given that four out of the five exercises required swallowing, which would likely exacerbate 
oral and throat pain, it is reasonable to suspect that poor compliance was related to the exercises 
causing pain.  A more comfortable PSE program may have resulted in improved compliance and 
subsequent improved outcomes.   
Kulbersh (2006) used similar prophylactic exercises as Carroll et al. (2008) and Kotz et al. 
(2012) but compared two different initiation timings of PSE.  He used a prospective cohort design 
comparing the effectiveness of PSE initiated two weeks prior to the onset of RT or CRT (pre-treatment; 
n=25) to PSE beginning the first day of RT or CRT (concurrent-treatment; n=12).  The Mendelsohn 
maneuver, Shaker, Masako maneuver (tongue-hold), tongue-resistance, and falsetto phonation1 were 
prescribed for both groups. All exercises except the Shaker were prescribed for 10 repetitions, five 
times per day.  The isometric Shaker was prescribed three times per day and the isokinetic Shaker was 
prescribed five times per day. The MD Anderson Dysphagia Inventory (MDADI) served as the sole 
outcome measure and was administered on average at nine months following completion of treatment 
                                                 
1 Only some patients were prescribed falsetto phonation. The authors did not indicate why. 
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for the pre-treatment group and 14 months, on average, for the post-treatment group. Overall, MDADI 
scores as well as individual domain scores were compared between the two groups.  The pre-treatment 
group had significantly better overall MDADI scores than the concurrent-treatment group as well as 
significantly better physical and emotional domain scores.  Functional domain scores followed the 
same trend but did not reach significance (p = .114).   
Three significant limitations exist for Kulbersh (2006).  First, the participants were not 
randomly assigned and hence, the groups were unbalanced.  Second, outcome assessment times 
differed.  The average assessment time for the pretreatment group was nine months, while the average 
assessment time for the control group was 14 months.  Delayed effects of radiation (i.e., fibrosis) may 
have affected the control group MDADI scores (O'Sullivan & Levin, 2003).  Thirdly, Kulbersh did not 
report compliance data; nor did he report that he controlled for differences in compliance between the 
two groups.  Given the relatively close onset times of PSE for the two groups, and the small sample 
sizes (particularly for the control group), controlling for compliance differences between the two 
groups is essential to isolate the effects of PSE initiation timing.  
Van der Molen et al. (2011) expanded on efficacy of prophylactic dysphagia intervention by 
investigating two different types of prophylactic exercise programs using a randomized control trial 
design. Each program consisted of range of motion stretches and strengthening exercises.  The 
“standard” group (n = 25) was prescribed range-of-motion exercises for the jaw and tongue and four 
strengthening exercises – gargle, effortful swallow, Masako maneuver, and super-supraglottic.  The 
“experimental” group (n = 30) was prescribed stretch exercises for the jaw using the Therabite device 
and a suprahyoid strengthening exercise consisting of “swallowing with the tongue elevated to the 
palate while maintaining mouth opening at 50% of its maximum” (p. 159).  The participants began 
exercises two weeks prior to the onset of CRT and were instructed to perform the exercises three times 
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per day. Three repetitions were prescribed per exercise session for each of the exercises, except for the 
ROM exercises, which were prescribed for five repetitions.  Outcome measures were taken prior to 
CRT and approximately 10 weeks following completion of CRT. Measures included MBS, maximum 
inter-incisor mouth opening (MIO), weight, body mass index (BMI), the functional oral intake scale 
(FOIS), a study-specific questionnaire on quality-of-life, and a visual analog scale for pain assessment 
(presumably swallowing pain).  Specific measures obtained from the MBS included the penetration-
aspiration scale (PAS) and the presence or absence of contrast residue in the pharynx.  Group 
comparisons revealed only one difference; the experimental group had less residue on cake at 10 weeks 
post-CRT than the standard group.  An effect size was not reported, preventing any conclusions 
regarding the extent of the difference.  This relative lack of group differences is particularly interesting 
in that the patients in the standard group were significantly more compliant with their exercises than 
those in the experimental group2; yet, the only significant outcome difference favored the experimental 
group.   
 Several weaknesses of van der Molen et al. (2011) are evident.  First, a no-PSE treatment 
control group was not included.  The authors point out that this “could not be avoided since 
withholding rehabilitation is no longer considered ethical according to the guidelines of the Dutch 
Head and Neck Cooperative Group” (p. 162).  This rationale is certainly legitimate; however, without a 
no-PSE treatment control group, and given the minimal differences between the groups, and lack of 
reported effect size on the one difference found, it is difficult to conclude that either exercise program 
was efficacious, or to what extent either program was of benefit. The authors did include a discussion 
of how their results compared to other studies in the literature that included no-treatment control 
                                                 
2 The mean total days patients practiced the exercises for both groups was 50 out of an approximate 120-day observation period. 
Mean = 59 days and 41 days for the standard and experimental groups, respectively (p = .05). 
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groups.  Their results were favorable to other studies in regards to PAS scores (Carroll et al., 2008) and 
weight change (Newman et al., 1998; Oates et al., 2007). Additionally, feeding-tube dependency rates 
at the end of treatment (76%) and 10-weeks post treatment (37%) were better than similar randomized 
studies done at their institution, which showed an average of 86% tube-dependency at the end of 
treatment and 62% tube-dependency at 12 weeks post-treatment (Ackerstaff et al., 2009).  A second 
weakness of the study is that the patients were only assessed at 10 weeks post-CRT, so differences 
between the groups before or after that period is unknown.  Lastly, and potentially most importantly, 
although the exercises in the standard group were similar to that of Carroll et al. (2008) and Kulbersh 
(2006), the dosage of the exercise programs was quite different.  Carroll et al. and Kulbersh prescribed 
10 repetitions five times per day, whereas van der Molen et al. prescribed 3-5 repetitions, three times 
per day.  The differences between van der Molen et al.’s exercise protocols should also be considered 
in light of the differences in dosage.  Van der Molen et al.’s experimental exercise program targeted 
primarily ROM of the jaw with only one exercise targeting swallowing strength, whereas the standard 
exercise protocol consisted of four swallowing strength exercises.  Further, the experimental strength 
exercise was intended to target only suprahyoid muscles, whereas the standard strength exercises 
targeted tongue-base retraction and pharyngeal contraction.  Given that tongue-base retraction and 
pharyngeal contraction are two of the most common pathophysiological impairments in patients with 
HNC treated with RT/CRT (Frowen & Perry, 2006; Hutcheson et al., 2008; Kotz et al., 2004; 
Logemann et al., 2008) it is surprising that a protocol that did not target either of these two swallowing 
functions was better than a protocol that did target these functions. It may be that this expected 
difference was not found due to the weak dosage of the standard exercises.  
  Carnaby-Mann and colleagues (2011) published the only PSE study that included assessment 
of muscle deterioration and composition using T2-weighted MRI. Their study was a randomized 
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control trial that included three groups.  Patients in the “usual care” group (n = 20) received sessions 
with an SLP during RT/CRT for education and monitoring. Patients in the “standard sham” group (n = 
18) completed a buccal extension exercise (“valcuff”) twice per day throughout RT/CRT.  The third 
group, termed the “pharyngocise” group (n = 20), completed daily swallowing exercises (4 cycles of 10 
reps, 2x/day) throughout RT/CRT that consisted of falsetto phonation, tongue press, effortful swallow, 
and jaw resistance/strengthening with the Therabite.  Outcome measures were administered at baseline, 
end of CRT, and six months post-treatment.  Only 31 participants (approximately 50% of each group) 
were assessed at six months post-treatment. Measures included MBS, FOIS, Mann Assessment of 
Swallowing Ability (MASA), smell and taste, saliva production, weight, QOL questionnaires, and T2-
weighted MRI.  The pharyngocise group was superior to the usual-care group in regards to muscle 
deterioration in the genioglossus, mylohyoid, and hyoglossus muscles, oral feeding maintenance, PEG-
tube dependence rate, salivary function, taste, and smell.  The pharyngocise group also demonstrated 
less decline in functional swallowing and mouth opening than both the usual-care and sham groups.  A 
significant advantage of this study was the inclusion of a sham PSE group, which controlled for a 
placebo effect.  The primary limitations of the study are: (1) the approximate 50% attrition rate by the 
six month post-treatment point, for which the authors did not provide a rationale, and (2) the lack of 
three-month post-treatment data.  
 Virani et al. (2015) designed the first PSE study to address the problem of PSE compliance.  
They compared a PSE program consisting of three common PSE swallowing exercises (“exercise 
group,” n = 26) to a simple and salient program consisting only of repetitive swallowing (“swallow 
group,” n = 24). The exercise group completed the Masako, pharyngeal squeeze, and shaker exercise. 
The Masako and pharyngeal squeeze exercises were prescribed at seven sets of 10 repetitions per set 
daily, while the Shaker exercise was performed at a frequency of three sets per day. Participants in the 
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“repetitive swallowing” group were prescribed 34 saliva and/or water swallows seven times per day. 
FOIS scores, MDADI scores, and PEG placement rates were compared at baseline, post-treatment, and 
at three months post-treatment.  FOIS and MDADI scores were not significantly different between the 
groups at any of the data collection points, but PEG tube dependence rates at three months post-
treatment were significantly lower in the exercise group than the swallow group, at 16% and 50%, 
respectively.  Compliance rates declined sharply in each group throughout the course of RT/CRT but 
were not significantly different between the groups. The primary limitations to Virani et al. (2015) 
include the following: (1) small number of participants, (2) lack of swallowing-pain measure, (3) lack 
of one month and six month post-treatment data.  
To date, one study has shown a lack of support for prophylactic dysphagia intervention in 
patients with HNC treated with RT/CRT.  Ahlberg et al. (2011) performed a prospective, 
nonrandomized cohort study comparing two groups of patients diagnosed with HNC and treated with 
RT.  The experimental group (n = 84) received PSE while the control group (n = 121) did not receive 
PSE. The prescribed PSE included 10 repetitions of the Mendelsohn maneuver and five repetitions of 
tongue range-of-motion stretches (out, up, down, laterally), one to two times a day.  Experimental 
participants were also prescribed strengthening and stretch exercises for the head and neck including 
flexion/active rotation of the head in both directions and lateral flexion/extension of the head.  The 
‘Acute Medic Jaw Trainer and Stretcher’ was also used to increase jaw range of motion.  It was 
prescribed for 10 repetitions of 20 seconds each, two times per day. The swallowing exercises 
(Mendelsohn and tongue range of motion) were initiated before RT and continued for three months 
following RT.  The head and neck strengthening and stretch exercises were also initiated before the 
start of RT but were continued until six months post-RT. Assessment measures used by Ahlberg et al. 
(2011) included clinical swallowing function, weight changes, two-year survival, health-related quality 
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of life (HRQOL), European Organization for Research and Treatment of Cancer (EORTC) 
questionnaires, Hospital Anxiety and Depression Scale (HADS), project specific questionnaire focused 
on self-reported functional losses, rehabilitation, and working ability. Measures were taken at baseline 
and six months post-RT/CRT (aside from two-year survival). Results revealed no positive effects of 
PSE. Furthermore, compared to patients who did not receive PSE, patients enrolled in PSE reported 
significantly more swallowing difficulty than those not enrolled in PSE.   
 Several differences between Ahlberg et al. (2011) and other PSE studies may explain the 
difference in findings.  At first glance, Ahlberg et al.’s large sample sizes and comprehensive outcome 
measures indicate a significant strength over the other PSE studies; however, other differences reveal 
weaknesses of Alberg et al.’s methodology and may explain the lack of apparent benefit of PSE. First 
is the issue of dosage.  Ahlberg et al. recommended two swallowing exercises (Mendelsohn and tongue 
range of motion), whereas each of the other PSE studies recommended three to five swallowing 
exercises.  Additionally, Ahlberg et al. recommended only five to 10 repetitions of each exercise, one 
to two times daily. Other PSE studies prescribed either multiple sets of each exercise, or to perform 
each exercise three to five times a day. Overall, this is a significant difference in dosage and the lack of 
differences in swallowing outcomes in the Ahlberg et al. study may be due to insufficient intensity of 
the PSE program.  
 An additional difference between Alberg et al.’s study and the other PSE studies is the 
proportion of patients with stage I or stage II cancer, and the proportion of patients who received 
adjunctive chemotherapy.  Approximately 30% of the patients included in Alberg el al.’s study had 
stage I or stage II cancer, and only 23% of the participants received adjunctive chemotherapy.  The 
other PSE studies included primarily patients with stage III or IV cancer3 and nearly all patients 
                                                 
3 Carbaby-Mann et al. (2011) did not report cancer stage of their participants. 
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received adjunctive chemotherapy.  Given that severity of RT/CRT toxicity-induced dysphagia is 
directly related to RT dose and adjunctive chemotherapy worsens the negative effects of RT (Forastiere 
et al., 2001), a disproportionate amount of patients getting lower doses of RT and no chemotherapy 
may have impeded a finding of group differences between the control and experimental groups in 
patients with advanced HNC.   
Several themes emerge from a review of previous PSE studies.  These themes provide direction 
for future research and informed the current study.  First, significant methodological variations are 
apparent across previous PSE studies, which impedes valid cross-study comparisons and 
reproducibility of results.  Methodological differences include timing of onset of PSE, exact PSE 
exercises prescribed, differences in dose and dose frequency, and differences in data collection times. 
Second, although numerous studies confirm that QOL is reduced in patients with HNC, and QOL is 
related to swallowing function and swallowing pain, few previous studies were designed with QOL in 
mind.  Some previous studies looked at QOL post RT/CRT but no previous studies attempted to create 
a PSE program that minimizes swallowing pain to minimize impacts on QOL during RT/CRT.  Lastly, 
every PSE study that discussed compliance reported it to be a problem, and Kotz et al. (2012) reported 
anecdotally that patients reported that one of the primary reasons for poor compliance was mouth and 
throat pain.    
The current study addressed three of these problems: (1) this study used similar methodology to 
other PSE studies in regards to exercises and dosage (Carnaby-Mann et al., 2011; Carroll et al., 2008; 
Kotz et al., 2012; Kulbersh, 2006; Virani et al., 2015), outcome measures (Carnaby-Mann et al., 2011; 
van der Molen et al., 2011; Virani et al., 2015), and schedule for collecting outcome measures 
(Carnaby-Mann et al., 2011; Kulbersh, 2006; Virani et al., 2015); (2) this study included a validated 
swallowing-related QOL instrument (the MDADI) to capture changes in swallowing-related QOL; and 
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(3) this study addressed the problem of compliance by contrasting a PSE program consisting solely of 
indirect (i.e., non-specific) swallowing exercises (exercises that do not require actual swallowing) to a 
PSE program consisting of a combination of indirect and direct (i.e., specific) swallowing exercises 
(exercises that require swallowing) in an attempt to create an effective program that minimizes patient 
discomfort and maximizes patient compliance. The program consisting of both direct and indirect 
exercises was very similar to previous PSE studies and served as the comparison group.   
 
 
 
 
 
 
 
 
 
Running head: TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC 
38 
 
 
Table 1 
Summary of prior studies on prophylactic swallowing exercises and key findings 
Authors N Exercises Dose/Dose 
Frequency 
Outcome 
measures 
Compliance Key Findings 
Carroll et al. 
(2008) 
9 treatment 
 
9 no-treatment 
control  
Mendelsohn 
Masako 
Tongue resistance 
Effortful swallow  
Shaker  
 
10 reps, 5x/day 
 
Shaker: 1 set/day 
 
1. MBS at 3 
months post 
2. G-tube status 
at 12 mo 
Not reported  Significant improvement in 
epiglottic inversion and tongue 
base position in the PSE group. 
No difference in G-tube 
removal time between groups. 
Kotz et al. (2012) 10 treatment  
 
11 usual care 
(no-tx)  
Effortful swallow 
Super–supraglottic 
swallow 
Tongue-hold 
maneuver 
Tongue retraction 
Mendelsohn 
maneuver 
 
10 reps, 3x/day  Pre-RT, 3, 6, 9, 
and 12 mo post-
RT: 
1. PSS-HN 
2. FOIS 
~70% ceased exs by 
week 5 due to pain 
and fatigue 
Better swallowing function in 
PSE pts at 3 and 6 mo post-RT 
but not immediately post-RT or 
at 12 mo. 
Kulbersh et al. 
(2006) 
25 treatment 
(exs onset 2 
wks pre-RT) 
 
12 control (exs 
onset first RT) 
Mendelsohn 
Masako 
Tongue resistance 
Falsetto voice (only a 
few pts) 
Shaker 
 
10 reps; 5x/day 
Shaker:  
   Isometric: 
3x/day 
   Isokinetic: 30 
reps, 5x/day  
 
MDADI at 6 to 12 
mo (median=9 
mo) 
Not reported Improved MDADI scores in the 
PSE group 
van der Molen et 
al. (2011) 
25 Standard 
 
 
 
 
 
25 Experimental 
Jaw and tongue ROM 
Gargling 
Masako 
Super-supraglottic 
 
Therabite stretch 
Therabite swallow 
Stand:  
  ROM: 3 reps, 
3x/day 
  Others: 5reps, 
3x/day 
Exp:  
  Stretch: 3 reps, 
3x/day 
  Swallow: 10 reps, 
3x/day 
Pre-RT, 10 wk 
post-RT: 
1. MBS (PAS) 
2. Maximum 
interincisor 
opening 
3. Weight change 
4. BMI 
5. FOIS 
6. Study-specific 
questionnaire 
Avg compliance of 
40% overall.  
Female > men.  
Stand grp > exp grp 
Significantly less cookie residue 
after treatment in exp group.  
 
No significant difference 
between the groups in PAS 
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7. Visual analog 
scale for pain 
 
Carnaby-Mann et 
al. (2011) 
20 usual care 
 
18 sham 
 
20 
pharyngocise 
No treatment 
 
Valchuff 
 
Falsetto, tongue press, 
hard swallow, 
therabite 
4 sets of 10 reps, 
2x/day (sham and 
pharyngocise) 
Pre-tx, post-tx, 
and at 6 mos post-
tx:  
1. T2-weighted 
MRI 
2. MBS 
3. FOIS 
4. MASA 
5 Mouth opening 
6. Saliva 
7. Smell and taste 
68% on avg overall; 
better compliance in 
sham group 
Greater perseveration of 
genioglossus, mylohyoid, and 
hyoglossus in pharyngocise 
group. No sig difference on 
FOIS or MBS. Less functional 
decline in swallowing (MASA 
score) in pharyngocise than 
usual care and sham groups. 
Better mouth opening and 
saliva in pharyngocise group 
than both sham and usual care 
groups.  
Virani et al. 
(2015)  
26 repetitive 
swallow 
24 exercise 
Repetitive swallows 
 
Masako 
Pharyngeal squeeze 
Shaker  
7 sets of 34 
swallows daily 
 
7 sets of 10 
reps/set daily 
Shaker: 3x/day 
Pre-tx, post-tx, 3 
months post-tx: 
1. FOIS 
2. MDADI 
3. PEG placement 
Gradual decline in 
both groups 
throughout 
RT/CRT. Less than 
60% by week 6  
Sig. less PEGs in exs group at 3 
mos post-tx across all patients. 
Sig. less PEGs in exs group at 
post-tx and 3 months in patients 
who received CRT.  No 
difference in FOIS or MDADI 
scores. 
Ahlberg et al. 
(2011) 
190 exp group 
 
184 no-
treatment 
Oral tongue 
ROM/stretch 
Mendelsohn 
Acute Medic JTS 
Stretching exs 
5 reps, 1-2x/day 
10 reps/1-2x/day 
10x20 sec, 2x/day 
3x10, 2x/day 
Pre-tx and 3 
months post-tx: 
1.Clinical swallow 
eval 
2. Weight  
3. Tongue, head, 
neck ROM 
4. Interincisor 
opening 
5. 3 QOL 
measures 
6. HADS 
7. Study-specific 
questionnaire 
Not reported No sig difference in weight loss 
or functional measures. Patients 
in exp group complained of 
swallowing difficulty more than 
those in no-tx group. 
Note:  exp = experimental; CRT = chemoradiotherapy; FOIS = functional oral intake scale; HADS = Hospital Anxiety and Depression Scale; MASA = Mann 
Assessment of Swallowing Ability; MBS = modified barium swallow; MDADI = MD Anderson Dysphagia Inventory; MRI = magnetic resonance imaging; mo = 
month(s); PAS = penetration-aspiration scale; PEG = percutaneous endoscopic gastrostomy; PSS-HN = Performance Status Scale for Head and Neck Cancer; QOL 
=   quality of life; RT = radiotherapy; reps = repetitions; pts = patients; sig = significant; tx = treatment. 
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Chapter 3: Methodology 
The Joint Investigational Review Board (JIRB) at Saint Patrick’s Hospital and Community 
Medical Center as well as The University of Montana IRB approved this non-randomized prospective 
study on September 16, 2012.  The study was in collaboration with the radiation oncologists at the 
Montana Cancer Center within Providence St. Patrick Hospital in Missoula, MT (Dr. Kathryn 
Markette, Dr. Margaret Menendez, and Dr. Jeffrey Stephenson), and Community Cancer Center in 
Missoula, MT (Dr. Michelle Proper), as well as the otolaryngologists at Rocky Mountain Ear, Nose, 
and Throat Center (Dr. Jeffrey Haller, Dr. Daniel Braby, Dr. Phillip Gardner). Data collection 
commenced from September 2012 to July 2015.  
Recruitment  
The primary role of the aforementioned physicians was participant recruitment.  The physicians 
informed patients that met the inclusion criteria of the study. Patients who were interested in learning 
more about the study filled out a simple contact-consent form, which was then faxed to the principal 
investigator (see Appendix A).  Patients were then contacted to set up an appointment in order to 
review the study protocol.  All participation was voluntary.   
The following inclusionary criteria were used to enroll patients:  
1) patients were diagnosed with stage III or IV squamous cell carcinoma of the 
tongue, palate, pharynx, or larynx; 
2) patients were treated with radiation with or without adjunctive chemotherapy 
(RT/CRT); 
3) patients were able to begin PSE exercises prior to the onset of RT/CRT;  
4) patients were at least 18 years of age;  
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5) patients were cognitively, mentally, and legally capable of making independent 
decisions regarding his/her personal medical care;  
The following exclusionary criteria were used: 
1) patients 18 years of age were excluded; 
2) patients who had undergone previous radiation treatment to the mouth, pharynx, or 
larynx were excluded; 
3) patients with a treatment including surgical dissection to the primary tumor were 
excluded if the surgical dissection resulted in dysphagia; 
4) patients suffering from dysphagia unrelated to the current cancer diagnosis were 
excluded;  
5) patients with any disease process other than their current HNC diagnosis that may 
have caused dysphagia were excluded (e.g., progressive neurological disease).  
Measures  
  Instrumental swallowing assessment. Each participant underwent a baseline instrumental 
swallow evaluation (i.e., MBS or FEES) to determine baseline swallowing function. A staff SLP and 
staff radiologist at St. Patrick’s Hospital or Community Medical Center Radiology departments 
performed the MBS exams. The protocol for each MBS was at the discretion of the SLP administering 
the exam. If for some reason the patient could not, or did not wish to, participate in the MBS, the 
participant underwent a FEES study.  All FEES exams were completed at The University of Montana 
Voice and Swallow Clinic by the principal investigator.   
Study-specific nutrition and pain questionnaire.  A one-page study-specific questionnaire 
was designed to obtain information on weight, oral intake measures (e.g., percent feeding tube use) and 
swallowing-related pain. This questionnaire can be seen in Appendix B.  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
42 
 
Functional Oral Intake Scale (FOIS): The Functional Oral Intake Scale (FOIS) is a 7-point 
scale of oral diet tolerance. It ranges from complete feeding tube dependence (level 1) to a full oral diet 
without restriction or compensation (level 7).  The FOIS was validated in the stroke population, which 
revealed excellent levels of inter-rater reliability (.86 to .91) and high consensual validity (.90). 
Criterion validity was also high at onset (r = .31 to .53) and at one month post-stroke (r = .46 to .76), 
relative to two measures of stroke severity and one measure of swallowing function. Additionally, the 
FOIS was associated with dysphagia severity (r = .54) and aspiration severity (r = .30) as measured by 
the modified barium swallow study (Crary, Mann, & Groher, 2005). The FOIS has been used in three 
previous prophylactic swallowing studies (Carnaby-Mann et al., 2011; van der Molen et al., 2011; 
Virani et al., 2015).  For the purposes of this study the FOIS was added to the nutrition and pain 
questionnaire (see Appendix B).      
MD Anderson Dysphagia Inventory (MDADI).  The MDADI is a self-administered, Likert-
type questionnaire designed and validated specifically for evaluating the impact of dysphagia on 
psychosocial QOL in patients treated for HNC.  It consists of 20 items and has global, emotional, 
functional, and physical subscales. An overall reliability coefficient of .96, test-retest reliability 
correlations for each subscale of .69 (global), .88 (emotional), .88 (functional), and .86 (physical), and 
criterion validity correlations of .47 to .61 indicate that it is an acceptable tool (Chen et al., 2001).  The 
MDADI was added partway through the study after further inspection of the literature indicated the 
importance of a measure of QOL. The MDADI was chosen over other validated QOL instruments 
because of its specificity to swallowing-related QOL, its ease of administration, and because it was 
used in two prior PSE studies (Kulbersh, 2006; Virani et al., 2015), which allowed for additional cross-
study comparisons. Because of its late addition to the study, the MDADI was not collected during the 
treatment-phase for the first six patients. The MDADI can be found in Appendix C. 
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Eating Assessment Tool-20 (EAT-20).  The EAT-20 is a symptom-specific, Likert-type, 20-
item survey instrument used to assess patient-reported dysphagia symptoms.  Original reliability testing 
of the EAT-20 revealed test-retest reliability for each single item ranging from .689 to .958 with the 
exception of one item, which scored .383 (Belafsky et al., 2008).  Belafsky et al. (2008) then eliminated 
the 10 items with the lowest test-retest reliability resulting in a 10-item survey (EAT-10). The current 
study used the EAT-20 rather than the EAT-10 because initial data for the current protocol was 
obtained with the EAT-20 rather than the EAT-10. One advantage of the EAT-20 is that many of the 
items contained in it, but eliminated from the EAT-10, speak to the impact of dysphagia on QOL (e.g., 
“I’m afraid to eat because of my swallowing problem.” “I’m afraid of choking in my sleep.” “My 
swallowing problem interferes with my work or other activities.”).  These specific items showed test-
retest reliability of .689, .780, .866, respectively, on the original testing of the EAT-20 (Belafsky et al., 
2008).  The EAT-20 can be seen in Appendix D.   
Given that many of the items on the EAT-20 spoke to swallowing-related QOL, the researchers 
chose to divide the EAT-20 into 1) physical, 2) emotional, and 3) functional subscales modeled after 
the MDADI. A qualitative correlate was created between the questions used in the EAT-20 and the 
questions listed in the physical, emotional, and functional subscales of the MDADI. Chronbach’s alpha 
coefficient was then applied to measure internal consistency within the EAT-20 subscales at the third 
data collection point (i.e., between the patient’s 23-25 RT treatment) and one month post-RT/CRT. 
Chronbach’s alpha scores were also calculated on the MDADI at one month post-RT/CRT as a 
comparison. Chronbach’s alpha scores for the EAT-20 ranged from .746 and .958, which are 
considered acceptable levels of internal consistency (Peterson, 1994). MDADI Chronbach’s alpha 
scores ranged from .659 to .827. The EAT-20 items in the physical, emotional, and functional 
subscales are provided in Table 2. Table 3 details the results of the reliability analysis.  
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Table 2 
 
EAT-20 items separated into physical, emotional, and functional subscales 
 
Item number Item description 
  
Physical 
1 My swallowing problem has caused me to lose weight. 
4 Swallowing liquids takes extra effort. 
5 Swallowing solids takes extra effort. 
6 Swallowing pills takes extra effort. 
8 Swallowing is painful. 
10 When I swallow food sticks in my throat.  
11 When I swallow food sticks in my chest.  
12 I cough when I eat. 
15 I get tired when I eat. 
18 I become short of breath when I eat.  
 
 Emotional 
9 The pleasure of eating is affected by my swallowing.  
13 I am afraid to eat because of my swallowing problem. 
14 My swallow problem is a burden to my family.  
16 I avoid eating in front of people. 
17 I’m afraid of choking in my sleep.  
19 People perceive me as sick because of my swallowing problem.  
20 Swallowing is stressful. 
 
 Functional 
2 My swallowing problem interferes with my ability to go out for meals. 
3 My swallowing problem interferes with my work or other activities. 
7 I have altered my diet because of my swallowing problem.  
 
Table 3 
 
Chronbach’s alpha coefficient measuring internal consistency within the EAT-20 sub-sets 
(physical, emotional, functional) at baseline and one month post-RT/CRT 
 
  
EAT-20 
Chronbach’s  coefficients 
MDADI 
Chronbach’s  coefficients 
During RT (data 3)   
    Physical .924 NA 
    Emotional .845 NA 
    Functional .814 NA 
1 Month Post-RT/CRT   
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    Physical .958 .659 
    Emotional .746 .827 
    Functional .779 .749 
 
Procedures  
Following review and signing of the informed consent form and the Health Insurance 
Portability and Accountability Act (HIPAA) release form (found in Appendices E and F), enrolled 
patients were placed into one of two prophylactic swallowing exercise (PSE) groups: 1) PSE that 
consisted of a combination of direct and indirect swallowing exercises (C-PSE), or 2) PSE that 
consisted solely of indirect swallowing exercises (ID-PSE).  Alternate assignment was used, except for 
the first participant, who was randomly assigned to the C-PSE group.   
The exercises for each group were chosen to target pathophysiological impairments common in 
patients with HNC treated with RT or CRT. As discussed in Chapter 2, they include but are not limited 
to: reduced tongue-base retraction (Chang et al., 2003; Hutcheson et al., 2008; Kotz et al., 2004; 
Logemann et al., 2008), reduced tongue strength and/or control (Lazarus et al., 2000; Logemann et al., 
2008), reduced range of motion of the jaw (M. L. Kent et al., 2007; Tang et al., 2011), weak pharyngeal 
contraction (Chang et al., 2003; Logemann et al., 2008), reduced laryngeal elevation and/or excursion 
(Chang et al., 2003; Hutcheson et al., 2008; Kotz et al., 2004; Logemann et al., 2008; Pauloski, 2008), 
and reduced or shortened opening of the UES (Hutcheson et al., 2008; Kotz et al., 2004; Logemann et 
al., 2008; Smith et al., 2000). Reduced epiglottic inversion is also listed as a common impairment 
(Chang et al., 2003; Hutcheson et al., 2008); however, it is relevant to point out that epiglottic inversion 
is a result of hyolaryngeal elevation and excursion. As such, it can only be targeted by targeting 
hyolaryngeal elevation/excursion. In addition to choosing exercises that target common 
pathophysiologic impairments, each of the exercises chosen were also used in previous prophylactic 
dysphagia treatment studies, to allow cross comparison with prior published studies. Table 4 
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summarizes the common pathophysiologic impairments in patients undergoing RT/CRT for HNC, the 
swallowing exercises that targeted each impairment in each treatment group, and the swallowing 
exercises used in prior PSE studies. 
Table 4 
 
Common pathophysiologic impairments due to RT/CRT toxicity, the exercises per group that target 
them, and the prior PSE studies that have included each of the exercises 
 
Pathophysiologic 
Target 
C-PSE 
Exercise 
Prior PSE studies including the 
exercise 
ID-PSE 
Exercise 
Prior PSE studies including 
the exercise 
Tongue-base 
retraction 
  
Effortful 
swallow 
Carnaby-Mann et al., Carroll 
et al., Kotz et al.,  
Tongue pull-
back 
Kotz et al. 
Tongue 
strength/control 
 
Effortful 
swallow 
Carnaby-Mann et al., Carroll 
et al., Kotz et al.  
Tongue ROM Ahlberg et al., van der 
Molen et al.,  
Jaw ROM Not targeted NA Jaw stretch  Ahlberg et al., Carnaby-
Mann et al., van der Molen 
et al. 
 
Pharyngeal 
contraction  
Effortful 
swallow 
 
Masako 
Carnaby-Mann et al., Carroll 
et al., Kotz et al., 
 
Carroll et al., Kotz et al., van 
der Molen et al., Virani et al.,  
 
Pharyngeal 
squeeze 
Kulbersh et al., Carnaby-
Mann et al., Virani et al.,  
Hyolaryngeal 
elevation/excursion  
Mendelsohn 
 
 
Shaker 
Ahlberg et al., Carroll et al., 
Kotz et al., Kulbersh et al.,  
 
Carroll et al., Kulbersh et al., 
Virani et al. 
Pharyngeal 
squeeze 
 
 
Shaker  
Kulbersh et al., Carnaby-
Mann et al., Virani et al., 
 
 
Carroll et al., Kulbersh et al., 
Virani et al. 
UES opening Mendelsohn 
 
 
Shaker  
Ahlberg et al., Carroll et al., 
Kotz et al., Kulbersh et al.,  
 
Carroll et al., Kulbersh et al., 
Virani et al. 
Shaker Carroll et al., Kulbersh et al., 
Virani et al. 
Note: NA not applicable, ROM range of motion, UES upper esophageal sphincter 
 
 
Dosage for each exercise was determined based on previous PSE studies, efficacy literature 
(when available), and clinical experience. Regarding dose frequency (i.e., number of treatment sessions 
per day), Carroll et al. (2008) and Kulbersh et al. (2006) prescribed PSEs five times per day while Kotz 
et al. (2012), van der Molen et al. (2011) and Virani et al. (2015) prescribed PSEs three times per day. 
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Given that exercise volume and inconvenience have been shown to impact compliance (Pollock et al., 
1998; Sluijs, Kok, & Zee, 1993), we felt that a frequency of three times per day was more appropriate 
than five times per day.  Repetitions per exercise session were adjusted when necessary to be 
comparable to prior PSE studies that used a dose frequency of five times per day, so that the total daily 
intensities were comparable.  
Combination Prophylactic Swallowing Exercises (C-PSE).  Patients in the C-PSE group 
were prescribed the following exercises: Mendelsohn, effortful swallow, Masako, and Shaker. The 
Mendelsohn was prescribed for 15 repetitions, three times per day (Carroll et al., 2008; Kulbersh, 
2006). The effortful swallow was prescribed for 20 repetitions, three times per day (Carroll et al., 
2008). The Masako was prescribed for 10 repetitions, three times per day (Kotz et al., 2012; van der 
Molen et al., 2011). The Shaker exercise consisted of one, one-minute hold, a rest period, then 20 
repetitions without any hold time (Kulbersh, 2006; Shaker et al., 2002; Virani et al., 2015).  The Shaker 
was also prescribed three times per day. The instructional handout provided to each patient can be 
found in Appendix G. 
Indirect Prophylactic Swallowing Exercises (ID-PSE).  Patients in the ID-PSE group were 
prescribed the following exercises: pharyngeal squeeze (i.e., falsetto “ee”), tongue-base retraction (i.e., 
finger-assisted tongue pull-back), lingual ROM, jaw ROM, and Shaker exercise. The pharyngeal 
squeeze exercise was prescribed for six repetitions, three times per day4. The tongue-base retraction 
and ROM exercises were each prescribed for 10 repetitions, three times per day (Kotz et al., 2012; 
                                                 
4 Given that typical maximum phonation time (MPT) is approximately 20 seconds for adults (R. Kent, Kent, & 
Rosenbek, 1987), patients who were not able to sustain phonation for at least 15 seconds, were prescribed 7- 10 
repetitions of the pharyngeal squeeze exercise.   
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Logemann et al., 1997). The Shaker exercise was prescribed as described above5. The instructional 
handout that was provided to each patient can be found in Appendix H. The study commenced in three 
phases.  
Training Phase. The training phase began with enrollment and ended the first day of RT/CRT. 
During the training phase, baseline data was collected including MBS or FEES, study-specific pain and 
nutrition questionnaire, FOIS, EAT-20, and the MDADI. Participants were also instructed in their 
exercise program and provided a written instruction handout as well as a paper tracking form for 
tracking compliance. Participants were seen for as many visits as necessary to verify that they 
thoroughly understood the program and could accurately execute the exercises independently. All 
participants were able to achieve independence within one to two sessions. Every effort was made to 
begin the swallowing exercises up to, but no more than, two weeks prior to RT/CRT onset; however, 
patients were accepted as long as they were able to begin PSE within one day of RT/CRT onset. Patient 
handouts and tracking forms for each exercise can be found in Appendices G through J.   
Treatment phase. The treatment phase began on the first day of the patient’s RT/CRT and 
continued until the final day of RT/CRT, generally 7-9 weeks. During the treatment phase, the 
investigators convened with each patient once during radiation doses 12 to 14, once during radiation 
dose 23 to 25, and on the last day of RT/CRT.  The nutrition and pain questionnaire, EAT-20, and 
MDADI were completed during each of these sessions. The data was collected either immediately 
before or immediately after RT for that day, at the preference of the patient.   
Post-treatment phase. The post-treatment phase consisted of the first six months following 
completion of RT/CRT. The investigator encouraged each patient to continue PSEs as prescribed 
                                                 
5 The Shaker exercise was assigned to both groups at the clinical judgment of the principal investigator, given its high 
validity for improving hyolaryngeal elevation/excursion and upper esophageal function, both common impairments in 
HNC patients. (Easterling et al., 2005; Mepani et al., 2008; Shaker et al., 2002) 
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during the post-treatment phase until they were able to resume full P.O. intake with minimal dysphagia 
symptoms. During the post-treatment phase, the investigator phoned each patient every one to two 
weeks to ensure recovery was occurring as expected. The investigator intended to request an 
appointment with the patient if he/she reported significant signs or symptoms of aspiration, or any other 
concerning complaints; however this this was not necessary for any of the patients who continued in 
the study. The nutrition and pain questionnaire, FOIS, EAT-20, and MDADI were collected at one 
month and three months post RT/CRT treatment. Most data was gathered over the phone unless the 
patient requested a paper-based survey be sent in the mail.  
Participants 
Twenty-four patients attended an initial meeting to review the protocol.  Twenty-two patients 
met the inclusion criteria and enrolled in the study.  One patient voluntarily dropped from the study 
within the first two weeks of enrollment. He stated that he did not feel he would be compliant with the 
study procedures or exercises. Three patients were dropped due to unwillingness/inability to provide 
data in line with the study protocol timeline and/or unwillingness or inability to complete an 
instrumental swallow study. One patient did not respond to a request for one month post-treatment 
data, four patients did not respond to a request for three month post-treatment data. Additionally, at the 
time of the current analysis, one patient was not yet at three months post-treatment point. This left a 
total of 18 patients at one month post-treatment and 14 patients at three months post-treatment. Figure 
1 provides a breakdown of participant counts at each data collection time point.   
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Figure 1. Breakdown of patient enrollment and attrition at each data time point.  
Group Demographics and Cancer Characteristics 
Table 5 catalogs demographic data and cancer characteristics including tumor site, tumor size 
(i.e., T1, T2, T3, or T4, T4 being the worst), nodal disease category (i.e., N1, N2, or N3, N3 being the 
worst) and cancer stage (i.e., III or IV, IV being the worst). Between-group differences were analyzed 
with the Mann-Whitney U test for ordinal and continuous variables and the Fisher’s exact test for 
nominal variables. There were no significant between-group differences on all demographic variables 
and cancer characteristics.  A total of 15 males and three females completed the initial phase of the 
study. The mean age for the C-PSE group was 60.78 years, with a range of 50-74 years. The mean age 
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N=9 
C-PSE (RT 23-25) 
N = 9  
C-PSE (RT 12-14) 
N = 9 
C-PSE (3 month post) 
N = 7 
ID-PSE (Last RT) 
N = 9 
ID-PSE (1 month post) 
N =8 
ID-PSE (Baseline) 
N=9 
ID-PSE (RT 23-25) 
N = 9 
ID-PSE (RT 12-14) 
N = 9 
ID-PSE (3 month post) 
N = 7 
TOTAL 
N=18 
TOTAL 
N=18 
TOTAL 
N=18 
TOTAL 
N=18 
TOTAL 
N=17 
TOTAL 
N=14 
Did not qualify = 2 
Voluntarily dropped after enrollment = 1 
Dropped due to non-compliance with protocol = 3 
 
Did not respond to data collection 
request = 4 
Not yet at 3 months post-treatment =1 
 
Did not respond to data collection 
request = 1 
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for the ID-PSE group was 60.22 years, with a range of 50-62 years. The mean age in years for the total 
population was 60.50, with a range of 45-74. The majority of patients in both groups had a tumor size 
of T1 or T2 (i.e., 6 out of 9 for both groups). The C-PSE group had two patients with T3 tumors and 
one patient with a T4 tumor; while the three remaining patients in the ID-PSE group had T3 tumors. 
All patients in the ID-PSE group had nodal scores of N2. Two patients in the C-PSE group had nodal 
scores of N1 and one patient had a nodal score of N3. All remaining patients in the C-PSE group had a 
nodal score of N2. Every patient had stage III or stage IV cancer. Eight patients in the ID-PSE group 
and seven patients in the C-PSE group had stage IV cancer.  Every patient’s primary tumor was located 
in the base of the tongue, tonsil, epiglottis, larynx, or oropharynx with a relatively equal distribution in 
each group. Every patient was treated with CRT except for one patient in the ID-PSE group who was 
treated with RT alone.  
Table 5 
 
Demographics and baseline data of participants including age, gender, tumor size, nodal disease, 
cancer stage, tumor site, PEG use, FOIS, EAT-20 scores at baseline.  Standard deviations in 
parentheses where applicable 
 
Variables C-PSE 
Group 
ID-PSE 
Group 
Total Test-Statistic p-value 
(2-tailed) 
No. of Patients 9  9 18 NA NA 
Age       
    Mean Age 60.78 (8.48) 60.22 (8.43) 60.50 
(8.21) 
Mann-Whitney 
U 
.796 
    Range 50-74 45-74 45-74 
Sex      
    Male 8 (89%) 7 (78%) 15 (84%) Fisher’s Exact 
Test 
.712 
    Female 1 (11%) 2 (22%) 3 (17%) 
Tumor Size      
    T1 3 (33%) 3 (33%) 6 (33%)   
    T2 3 (33%) 3 (33%) 6 (33%) Mann-Whitney 
U 
.406 
    T3 2 (22%) 3 (33%) 5 (28%)   
    T4 1 (11%) 0 (0%) 1 6%)   
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Nodal disease      
    N1 2 0 2   
    N2 6 9 15 Mann-Whitney 
U 
.540 
    N3 1 0 1   
Cancer Stage      
   Stage III 2 (22%) 1 (11%) 3 (17%) Fisher’s Exact 
Test 
.712 
   Stage IV 7 (78%) 8 (89%) 15 (83%) 
Tumor site      
    Tonsil 3 (33%) 2 (22%) 5 (28%) 
Mann-Whitney 
U 
 
    Base of tongue 4 (44%) 3 (33%) 7 (39%)  
    Epiglottis 1 (11%) 2 (22%) 3 (17%) .406 
    Oropharynx  0 (0%) 1 (11%) 1 (6%)  
    Larynx 1 (11%) 1 (11%) 2 (11%)  
Treatment       
    RT alone 0 (0%) 1 (11%) 1 (6%) Fisher’s Exact 
Test 
.500 
    CRT  9 (100%) 8 (89%) 17 (94%) 
Mean Exs days pre-
RT/CRT 
11.56 (6.56) 16.78 
(12.99) 
14.17 
(10.34) 
Mann-Whitney 
U 
.399 
Note: CRT = chemoradiotherapy; Exs = exercises; FOIS = functional oral intake scale; PEG = 
percutaneous endoscopic gastrostomy; RT = radiotherapy 
 
Baseline Outcomes 
Table 6 summarizes baseline outcome data including percentage PEG use, swallowing pain, 
FOIS, and EAT-20. The MDADI is not included due to baseline data missing for six patients. 
Essentially all patients had functional swallowing and minimal complaint of swallowing difficulty at 
baseline except for patient 13 in the ID-PSE group who had severe dysphagia at baseline due to the size 
of her tumor. This patient was subsequently 100% PEG-tube dependent at baseline and scored 2-4 
standard deviations outside the mean on all baseline measures (Table 7). This resulted in higher 
baseline scores on all measures in the ID-PSE group relative to the C-PSE group.  This difference was 
not statistically significant. Every other patient reported functional swallowing at baseline. Swallowing 
pain was scored on a scale from 0-5, with 0 being no pain and 5 being the worst pain. Mean 
swallowing pain at baseline was .78 and .89 for the C-PSE and ID-PSE groups, respectively. The FOIS 
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is scored on a 1-7 scale with 1 being fully dependent on a feeding tube and able to take nothing by 
mouth and 7 being able to eat an oral diet without any restrictions. Mean baseline FOIS scores were 
6.89 and 6.11 for the C-PSE and ID-PSE groups, respectively. EAT-20 scores followed a similar 
pattern with the mean EAT-20 Total score being 20.11 for the ID-PSE group and 3.78 for the C-PSE 
group. Table 6 catalogues mean baseline scores on each outcome measure.  
 
Table 6 
 
Baseline outcome data including percentage PEG use, swallowing pain, FOIS, and EAT-20.  
Variables C-PSE Group 
(n = 9) 
ID-PSE Group 
(n = 9) 
Total Test p-value 
(2-tailed) 
Mean PEG use (0-5) 0 .56 (1.67) .278 (1.18) Mann-Whitney U .317 
Mean swallowing pain (0-5) .78 (.83) .89 (1.36) .83 (1.10) Mann-Whitney U .811 
Mean FOIS 6.89 (.33) 6.11 (1.97) 6.5 (1.42) Mann-Whitney U .248 
Mean EAT-20 TOTAL 3.78 (6.61) 20.11 (34.88) 11.94 
(25.76) 
Mann-Whitney U 
.343 
    Mean EAT-20 Physical 2.78 (4.32) 10.44 (18.53) 6.61 (13.63) Mann-Whitney U .523 
    Mean EAT-20 Emotional .667 (1.66) 6.11 (11.66) 3.39 (8.55) Mann-Whitney U .269 
    Mean EAT-20 Functional .33 (.71) 3.56 (5.62) 1.94 (4.22) Mann-Whitney U .226 
Note: EAT = Eating Assessment Tool; FOIS = Functional Oral Intake Scale; PEG = percutaneous 
endoscopic gastrostomy tube 
 
Table 7  
 
Total group means contrasted with patient 13’s individual scores on baseline measures and the 
standard deviations away from the total group mean for patient 13 
 
Total group mean Patient 13 score 
Standard deviations from 
the mean 
Percent PEG use (0-5) .278 (1.18) 5 4.00 
Swallowing pain (0-5) .83 (1.10) 4 2.88 
FOIS (7-1) 6.5 (1.42) 1 3.87 
EAT-20 Physical 6.61 (13.63) 56 3.62 
EAT-20 Emotional 3.39 (8.55) 33 3.56 
EAT-20 Functional 1.94 (4.22) 14 2.86 
EAT-20 Total  11.94 (25.76) 103 3.53 
Note: EAT-20 = Eating Assessment Tool-20; FOIS = Functional Oral Intake Scale; PEG = percutaneous 
endoscopic gastrostomy 
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In addition to swallowing pain, FOIS, and EAT-20 scores, baseline instrumental swallow study 
(i.e., modified barium swallow (MBS) or fiberoptic endoscopic evaluation of swallowing (FEES)) 
results were reviewed. The results of the instrumental studies were consistent with patient reports in 
that every patient in the entire cohort had functional swallowing ability aside from patient 13 of the ID-
PSE group. Patient 13’s MBS study confirmed severe aspiration on every consistency and an unsafe 
swallow. No other patients had aspiration. Three patients in the ID-PSE group and one patient in the C-
PSE group had mild penetration without aspiration on thin liquids. Four patient in the ID-PSE group 
and three patients in the C-PSE group had very mild pharyngeal post-swallow residue that cleared 
easily with an extra swallow. No other remarkable findings were reported.   
Statistical Analysis 
All statistical analyses were performed using IBM SPSS v 22 (SPSS, Inc., Chicago, IL) 
software.  Histograms and Q-Q plots of the data revealed evidence of non-normal distributions in a 
majority of the variables at each time point.  Further, the sample sizes were arguably too small to allow 
accurate assessment of distributional assumptions (Field, 2013a). Inability to determine distributional 
assumptions necessitated the use of non-parametric tests. The Mann-Whitney U test was chosen as the 
most appropriate non-parametric test for ordinal and continuous variables. The data met the following 
assumptions required for the Mann-Whitney U test: 1) the dependent variable was measured at the 
continuous or ordinal level, 2) the independent variable was dichotomous, and 3) the observations were 
independent (Mann whitney U test in SPSS.). Further, Pero-Cebollero and Guardia-Olmos (2013) 
found the Mann-Whitney U test to have the lowest error rate relative to other non-parametric tests that 
compare two independent groups, particularly with small sample sizes. The correlation coefficient was 
used as an effect size when using the Mann-Whitney U test (Field, 2013c). The Fisher’s exact test was 
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used to test between-group differences on nominal variables due to violation of the chi-square 
distribution assumption (Field, 2013b).  
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Chapter 4: Results 
The purpose of this study was to determine if a prophylactic swallowing exercise (PSE) 
program consisting solely of indirect swallowing exercises (ID-PSE) results in the following outcomes: 
1) better compliance, 2) better oral intake, 3) better swallowing-related QOL, and 4) less swallowing 
pain than a PSE program consisting of a combination of indirect swallowing exercises and direct 
swallowing exercises (C-PSE).  The precipitance for the study was poor compliance from patients in 
prior PSE studies that we hypothesized was due to swallowing pain that was exacerbated by direct 
swallowing exercises. 
Compliance 
 Compliance was tracked with a paper-tracking sheet filled out by each patient at home and 
returned to the investigator at data collection time points.  A compliance percentage was calculated per 
patient for the pre-RT/CRT phase and each week for weeks 1 to 8 during RT/CRT.  Additionally, total 
compliance for weeks 1 to 4, and weeks 4 to 7 during RT/CRT, as well as an overall compliance was 
calculated for each group.  Compliance for each group declined gradually throughout RT/CRT.  
Overall compliance was 42% and 47% for the C-PSE and ID-PSE groups, respectively. The C-PSE 
group began with a mean compliance of 58% in the pre-RT/CRT phase and declined to 39% at week 
seven. Compliance for the ID-PSE group began at 62% in the pre-RT/CRT phase and declined to 48% 
at week seven.  Mean compliance for the first half of RT/CRT (i.e., weeks 1-4) was 43% and 51% for 
the C-PSE and ID-PSE groups, respectively. Mean compliance for the second half of RT/CRT (i.e., 
weeks 4-7) was 38% and 41% for the C-PSE and ID-PSE groups, respectively. Figure 2 depicts 
compliance rates per group from the pre-RT/CRT phase and weekly through week seven of RT/CRT.  
The Mann-Whitney U test revealed no statistically significant between-group differences for overall 
total compliance (U = 18, z = -044, p = .50, r = -.01), compliance during the first half of RT/CRT (U = 
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18, z = .353 p = .37, r = .08), and compliance during the second half of RT/CRT (U = 17, z = .097, p = 
.50, r = .02).  Tables 8-9 and Figures 2-3 depict these results.   
Table 8 
 
Mean compliance rates, standard deviations, and ranges pre-RT/CRT and weekly during RT/CRT 
 C-PSE ID-PSE Groups Combined 
 Compliance 
(%) 
SD Range 
Compliance 
(%) 
SD Range 
Compliance 
(%) 
SD  
Pre-RT/CRT .58 .42 .10-1.0 .62 .36 .15-1.0 .60 .38 
Week 1 .50 .37 0-1.0 .58 .38 0-1.0 .54 .36 
Week 2 .42 .41 0-1.0 .56 .37 0-.92 .49 .38 
Week 3 .43 .43 0-1.0 .49 .39 0-.97 .46 .40 
Week 4 .36 .45 0-1.0 .43 .39 0-1.0 .40 .41 
Week 5 .39 .47 0-1.0 .38 .44 0-1.0 .38 .44 
Week 6 .39 .48 0-1.0 .29 .38 0-1.0 .34 .42 
Week 7 .53 .47 0-1.0 .23 .42 0-1.0 .38 .43 
Note: SD = standard deviation 
 
Table 9 
 
Mean compliance rates for the first half and second half of the RT/CRT phase 
as well as total compliance per group. P-value based on the Mann-Whitney U 
test 
 C-PSE ID-PSE p-value  
(1-tailed) 
Weeks 1-4 .43 .51 .365 
Weeks 4-7 .38 .41 .50 
Total .42 .47 .50 
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Figure 2. Mean compliance per group from pre-RT/CRT through week seven of RT/CRT 
 
 
 
Figure 3. Mean compliance per group for the first and second half of RT/CRT 
 
Oral Intake  
 Oral intake was measured with percentage PEG tube use and the Functional Oral Intake 
Scale (FOIS). The patient estimated his/her average PEG tube use relative to his/her total intake 
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(i.e., orally and PEG) at the time of each data collection time point using a 0-5 scale (i.e., 0=0-
10%; 1 = 10-25%; 2 = 25-50%; 3 = 50-75%; 4 = 75-90%; 5 = 90-100%).  The investigator 
determined the FOIS score based upon what the patient reported he/she was consuming orally.  
An FOIS score of 7 indicated full oral intake with a non-restrictive diet and a score of 1 indicated 
complete dependence on the PEG tube. As expected PEG tube use and FOIS scores had an 
inverse relationship with PEG tube use scores gradually increasing throughout the RT/CRT phase 
and then gradually decreasing in the post-RT/CRT phase, and FOIS scores gradually decreasing 
through the RT/CRT phase and then gradually increasing in the post-RT/CRT phase.  Mean PEG 
tube use score for the C-PSE group was 0 at baseline, 3.33 at the final RT session, and .429 at 
three months post RT/CRT. While mean FOIS score for the C-PSE group was 6.879 at baseline, 
3.56 at the final RT session, and 6.14 at three months post RT/CRT.  Mean PEG tube use scores 
for the ID-PSE group were .56 at baseline, 4.11 at the final RT session, and .71 at three months 
post RT/CRT.  Mean FOIS scores for the ID-PSE group was 6.11 at baseline, 2.56 at the final RT 
session, and 5.86 at three months post RT/CRT. Visual inspection of the data indicated no 
evidence of a significant difference in FOIS scores between the two groups, but some potential of 
a significant difference between the two groups for PEG use at RT 23-25 and the end of RT 
(Figure 4). However, the Mann-Whitney U test revealed no statistically significant between-group 
differences on PEG use or FOIS scores at any time point.  Tables 10 and 11 and Figures 4 and 5 
summarize mean PEG use and FOIS scores at each time point.  
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Table 10  
 
Mean PEG use, standard deviations, and ranges at baseline, RT 12-14, RT 23-25, Final RT, one month post-RT/CRT, and three 
months post-RT/CRT. Statistical significance by Mann-Whitney U test  
 
 C-PSE                        ID-PSE  
 
PEG use SD Range  PEG use SD Range 
 
U 
 
Effect size 
p-value              
(1-tailed) 
Baseline 0 0 0  .56 1.67        0-5 36.0 .24 .365 
RT 12-14 1.78 2.17 0-5  2.0 2.45 0-5 37.5 -.06 .398 
RT 23-25 2.67 2.55 0-5  3.78 2.17 0-5 35.5 -.012 .333 
Final RT 3.33 2.5 0-5  4.11 1.83 0-5 34.5 -.15 .303 
1 month post 2.0 2.45 0-5  1.88 2.17 0-5 34.5 -.03 .444 
3 month post .429 1.13 0-3  .71 1.89 0-5 31.5 -.02 .479 
Note. SD = standard deviation 
 
Table 11 
 
Mean FOIS scores, standard deviations, and ranges at baseline, RT 12-14, RT 23-25, Final RT, one month post-RT/CRT, and 
three months post-RT/CRT. Statistical significance by Mann-Whitney U test  
 
 C-PSE  ID-PSE    
 
FOIS SD Range  FOIS SD Range 
U Effect size   p-value              
(1-tailed) 
Baseline 6.89 .33 6-7  6.11 1.97 1-7 31.0 -.27   .124 
RT 12-14 4.33 1.87 2-7  4.56 2.01 2-7 36.5 -.09 .358 
RT 23-25 3.56 2.01 1-6  3.00 1.73 2-6 34.5 -.14 .284 
Final RT 2.78 1.99 1-6  2.56 1.01 2-5 35.0 -.12 .301 
1 month post 3.89 1.97 1-6  4.75 1.91 3-7 25.0 -.26 .139 
3 month post 6.14 1.46 3-7  5.86 1.77 2-7 21.0 -.02 .312 
Running head: TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC 
61 
 
Note. FOIS = Functional Oral Intake Scale; SD = standard deviation 
 
 
   
Figure 4. Mean PEG tube use from baseline to three months post-RT/CRT. C-PSE = combination 
prophylactic swallowing exercise group; ID-PSE = indirect PSE group; PEG = percutaneous 
endoscopic gastrostomy; RT = radiotherapy 
 
   
Figure 5. Mean FOIS scores from baseline to three months post-RT/CRT. C-PSE = combination 
prophylactic swallowing exercise group; ID-PSE = indirect PSE group; FOIS = Functional Oral 
Intake Scale; mo = month; RT = radiotherapy 
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 In addition to PEG-use rates, patients who were dependent on a PEG-tube at the final 
RT/CRT session were asked to provide the first date they no longer required the use of the PEG-
tube for nutritional supplement. In some instances, patients were not able to recall the exact date, 
but were able to give an approximation. Enough data was obtained to determine PEG-
discontinuation rates at one month, two months, and three months post-RT/CRT. PEG-
discontinuation rates were used rather than PEG-discharge rates because the time between 
discontinuation of PEG use and PEG discharge varied greatly across patients. For instance, one 
patient in the ID-PSE group indicated that she stopped using her PEG-tube over three months 
before she had it removed. PEG-discontinuation rate was, therefore, thought to be a more accurate 
representation of PEG dependence than PEG-discharge rate.  
Six of nine patients (66%) in the C-PSE group and eight of nine patients (89%) in the ID-
PSE group were using a PEG tube at the final RT/CRT session. Of these patients, data was 
missing for one patient in the C-PSE group at two and three months post-RT/CRT and for one 
patient in the ID-PSE group at one month post-RT/CRT. By one month post, 50% (3/6) of the C-
PSE patients and 29% (2/7) of the ID-PSE patients had discontinued using their PEG tube. By 
two months post, 80% (4/5) of the C-PSE patients accounted for, and 63% (5/8) of the ID-PSE 
patients had discontinued using the PEG-tube. This rate did not change at three months post-
RT/CRT for the C-PSE patients, but improved to 88% (7/8) for the ID-PSE patients. Table 12 and 
Figure 6 provides these descriptive statistics. Significance tests using the Fisher’s exact test did 
not reveal any significant between-group differences at one month post-RT/CRT (p = .296), two 
months post-RT/CRT (p = .50), or three month post-RT/CRT (p = .50).   
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Table 12 
 
PEG-tube discontinuation rates at the end of RT, one month post-RT, two months post-RT/CRT, and three months 
post-RT/CRT. P-value by Fisher’s Exact test 
 
 C-PSE Group  ID-PSE Group        Total   
 N PEG d/c rate 
(%) 
 N PEG d/c rate 
(%) 
 N PEG d/c rate 
(%) 
p-value 
Final-RT 6 0  8 0  14 0 NA 
1-mo post RT 6 .50  7 .29  13 .40 .296 
2-mo post RT 5 .80  8 .63  13 .72 .50 
3-mo post RT 5 .80  8 .88  13 .84 .50 
Note. d/c = discontinuation; PEG = percutaneous endoscopic gastrostomy; mo = month; RT = radiotherapy 
 
 
 
 
Figure 6. Percent of patients who discontinued PEG-tube use at the final-RT, one month, two 
months, and three months, post-RT/CRT.  
Swallowing Function 
 Swallowing function was measured with the Eating Assessment Tool-20 (EAT-20) and 
the MD Anderson Dysphagia Inventory (MDADI). As explained in Chapter 3 of this dissertation, 
the MDADI was added late in the data collection process and so was not collected on the first six 
patients.  
Eating Assessment Tool-20 (EAT-20). As described in the Measures section of Chapter 3, 
the EAT-20 scores were divided into physical, emotional, and functional subscales modeled after 
the MDADI. Higher scores on the EAT-20 indicated worse self-perceived swallowing function. 
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As expected, EAT-20 scores increased progressively in both groups during RT/CRT and then 
gradually declined during the post-RT/CRT phase. Scores were similar between both groups at 
each point during the treatment phase of the study as can be seen in Figure 7. At one month post-
RT/CRT, EAT-20 scores were higher in the C-PSE group than the ID-PSE group. One month post 
scores for the C-PSE group and ID- 
PSE group respectively were as follows: EAT-20-Total: 31.67 vs. 16.88, EAT-20-P: 17.44 vs. 
3.87, EAT-20-F: 6.11 vs. 3.87, and EAT-20-E: 8.11 vs. 5.25. At three months the pattern reversed 
and favored the C-PSE group on all EAT-20 scores except for the EAT-20-F score. Scores at 
three months post-RT/CRT for the C-PSE and ID-PSE groups respectively were as follows: EAT-
20-Total: 6.14 vs. 13.86, EAT-20-P: 2.71 vs. 7.43, EAT-20-F: 2.00 vs. 2.00, and EAT-20-E: 1.43 
vs. 4.43. This reversal pattern that favored the C-PSE group at three months post-RT/CRT was 
exclusively due to patient 13 of the ID-PSE group, who was the only patient in both groups whose 
scores actually worsened from one month post to three months post. As can be seen in Figures 9, 
11, and 13, when patient 13 was excluded from the data, EAT-20 means for the ID-PSE group 
were relatively equivalent or lower than the C-PSE means at three months post-RT/CRT. All 
mean EAT-20 scores in the post-treatment phase are included in Table 13. 
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Figure 7. Mean EAT-20 subscale scores during RT/CRT. EAT = Eating Assessment Tool; E = 
emotional subscale; F = functional subscale; P = physical subscale. 
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Table 13 
 
Mean EAT-20-Total and EAT-20 subscale scores at the end of RT/CRT and during the post-RT/CRT phase. Standard deviations in 
parentheses 
 
            Final RT session 1 month post-RT/CRT 3 months post-RT/CRT 
 EAT-
20-Total 
EAT-
20-P 
EAT-
20-F 
EAT-
20-E 
 EAT-
20-Total 
EAT-
20-P 
EAT-
20-F 
EAT-
20-E 
 
EAT-
20-Total 
EAT-
20-P 
EAT-
20-F 
EAT-
20-E 
C-PSE Group 63.38 
(34.41) 
34.5 
(20.84) 
11.13 
(4.16) 
17.75 
(11.47) 
 
31.67 
(35.13) 
17.44 
(21.80) 
6.11 
(5.84) 
8.11 
(9.18) 
 
6.14 
(7.53) 
2.71 
(2.81) 
2.00 
(4.00) 
1.43 
(1.81) 
ID-PSE Group 67.00 
(27.34) 
36.44 
(16.43) 
11.56 
(3.88) 
19.00 
(9.15) 
 
16.88 
(18.07) 
7.75 
(7.83) 
3.87 
(3.98)  
5.25 
(6.58) 
 
13.86 
(21.64) 
7.43 
(11.09) 
2.00 
(3.41) 
4.43 
(7.44) 
Note. EAT = Eating Assessment Tool; E = Emotional subscale; F = Functional subscale P = Physical subscale; RT = radiotherapy; CRT = 
chemoradiotherapy 
 
 
 
Figures 8 and 9. Mean EAT-20-P scores during the post-RT/CRT phase with patient 13 (left) and with patient 13 excluded (right).  
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Figures 10 and 11. Mean EAT-20-F scores during the post-RT/CRT phase with patient 13 (left) and with patient 13 excluded (right).  
 
Figures 12 and 13. Mean EAT-20-E scores during the post-RT/CRT phase with patient 13 (left) and with patient 13 excluded (right). 
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To analyze between-group differences in the post-RT/CRT phase, difference scores were 
calculated for each patient by subtracting the one month and three month post-RT/CRT EAT-20 scores 
from the final-RT EAT-20 scores.  Analysis of between-group differences on the difference scores 
using the Mann-Whitney U test revealed a significant difference in the EAT-20-Total difference scores 
for one month post-RT/CRT (U = 49, z = 1.79, p = .042, r = .45) indicating that overall patients in the 
ID-PSE group had better self-perceived swallowing function at one month post-RT/CRT than patients 
in the C-PSE group. Difference scores on the EAT-20-P (U = 47, z = 1.58, p = .065, r = .39) 
approached significance. There were no significant differences in EAT-20-E (U = 42.5, p = .14) or 
EAT-20-F (U = 45, p = .10) one month difference scores. To determine if the lack of significance on 
the EAT-20-P, EAT-20-E, and EAT-20-F one month difference scores was due to patient 13, the same 
analyses were completed with patient 13’s data excluded. Excluding patient 13 did not result in any 
significant between-group differences and minimal changes in significance levels. There were no 
significant between-group differences for three months post-RT/CRT difference scores (all patients 
included). Mean one month and three month difference scores are catalogued in Table 14. Mean ranks 
and significance test results are catalogued in Table 15. 
Table 14 
 
Mean difference scores on the EAT-20 subscales at one month post-RT/CRT and three months post-RT/CRT.  
Difference scores calculated by subtracting one and three month post-RT/CRT scores from the final-RT 
scores. Standard deviations in parentheses 
 
 C-PSE Group  ID-PSE Group 
  N Diff. score Range        N Diff. score Range 
EAT-20-Total        
1 month post 8 28.00 (22.44) 1-64  8 47.63 (24.37) 14-81 
3 months post 6 54.00 (33.67) 7-109  7 51.00 (28.99) 14-84 
EAT-2-Emotional        
1 month post 8 8.63 (8.62) 0-25  8 13.00 (8.97) 3-26 
3 month post 6 16.33 (11.15) 3-37  7 12.57 (8.16) 3-24 
EAT-20-Functional        
1 month post 8 4.38 (4.96) -1-14  7 7.25 (4.06) 1-12 
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3 month post 6 7.67 (6.06) -1-15  7 8.86 (4.81) 1-13 
EAT-20-Physical        
1 month post 8 15.00 (16.96) 2-57  8 27.38 (15.27) 10-49 
3 month post 6 30.00 (20.91) 2-57  7 29.57 (16.87) 9-51 
Note. Diff = difference 
 
Table 15 
 
Mean ranks for EAT-20 subscale difference scores at one month post-RT/CRT and three months post-
RT/CRT. Z-score, p-value, and effect sizes determined by Mann-Whitney U test 
 
 C-PSE Group     ID-PSE Group     
 
N 
Mean 
Rank 
 N 
Mean 
Rank 
z-score U 
p-value  
(1-tailed) 
Effect size 
(r) 
EAT-20-Total          
     1 month post  8 6.38  8 10.62 1.79 49.00 .04* .45 
     3 month-post 6 7.00  7 7.00 0 21.00 .50 0 
EAT-20-E          
     1 month-post 8 7.19  8 9.81 1.10 42.50 .14 .28 
     3 month-post 6 7.42  7 6.64 -.360 18.50 .37 -.09 
EAT-20F          
     1 month-post 8 6.88  8 10.12 1.38 45.00 .10 .35 
     3 month-post 6 6.50  7 7.43 .432 24.00 .37 .12 
EAT-20-P          
     1 month-post 8 6.62  8 10.38 1.58 47.00 .065 .40 
     3 month-post 6 7.08  7 6.93 -.072 20.50 .47 -.02 
Note. CRT = chemoradiotherapy; NA = not applicable, MDADI = MD Anderson Dysphagia Inventory; RT = 
radiotherapy 
*Significant at alpha level = .05 
 
 MD Anderson Dysphagia Inventory (MDADI). MDADI scores were only available for 
four C-PSE patients and six ID-PSE patients at the final-RT/CRT time point, five C-PSE patients 
and seven ID-PSE patients at one month post, and four C-PSE and seven ID-PSE patients at three 
months post. The MDADI is scored according to global (MDADI-G), emotional (MDADI-E), 
functional (MDADI-F), and physical (MDADI-P) subscales. Subscale sums are transformed to a 
0-100 point scale with 0 being the worst functioning and 100 being the best functioning. Mean 
MDADI subscale scores for the C-PSE and ID-PSE groups at the final RT/CRT session were: 
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global 30 vs. 60, emotional 55.83 vs. 78.89, functional 66 vs. 72.67, and physical 52.50 vs. 58.33, 
respectively. Between-group differences in MDADI scores at the final RT session were analyzed 
with the Mann-Whitney U test, which revealed insignificant differences in the MDADI-F (U = 
15, p = .305) and MDADI-P (U = 14, p = .381) subscales, but a significant difference on the 
MDADI-E subscale (U = 21, z = 1.92, p = .034, r = .61) and a near significant difference on the 
MDADI-G (U = 20, z = 1.92, p =.057, r = .61). This indicated that the ID-PSE group had better 
swallowing related emotional QOL and probable better global swallowing-related QOL at the end 
of RT/CRT than the C-PSE group. Mean MDADI scores at the end of RT/CRT are shown in 
Figure 14 and Table 16. Table 17 summarizes mean ranks and test statistics.  
 
Figure 14. MDADI scores at the final RT/CRT session. MDADI = MD Anderson Dysphagia 
Inventory 
 
 Mean MDADI scores for the C-PSE and ID-PSE groups at one month post-RT/CRT 
favored the ID-PSE group and were as follows: global 64.00 vs. 77.14, emotional 64.67 vs. 86.67, 
functional 54.40 vs. 83.43, and physical 55.50 vs. 71.07, respectively.  At three months post-
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RT/CRT MDADI scores on all subscales were very similar between the two groups with mean 
global scores of 95.00 vs. 82.86, mean emotional scores of 95.00 vs. 92.86, mean functional 
scores of 92.00 vs. 91.43, and mean physical scores of 76.88 vs. 72.86, respectively. These scores 
are summarized in Table 16 and Figures 15-18. 
Table 16 
 
Mean MDADI scores at the final-RT session, one month post-RT/CRT, and three months post-RT/CRT. 
Standard deviations in parentheses 
 
 C-PSE Group  ID-PSE Group 
 Final-RT  1-mo post  3-mo post  Final-RT  1-mo post  3-mo post 
 
N Mean (SD)  N 
Mean 
(SD) 
 
N 
Mean 
(SD) 
 N 
Mean 
(SD) 
 
N 
Mean 
(SD) 
 
N 
Mean 
(SD) 
MDADI-G 
 
4 
30 
(11.55) 
 5 
64.00 
(32.86) 
 4 
95.00  
(10.00) 
 6 
60.00 
(30.98) 
 7 
77.14 
(17.99) 
 7 
82.86 
(29.28) 
MDADI-E 
 
4 
55.83 
(11.34) 
 5 
64.67 
(11.45) 
 4 
95.00 
(4.30) 
 6 
78.89 
(18.82) 
 7 
86.67 
(13.19) 
 7 
92.86 
(8.48) 
MDADI-F 
 
4 
66.00 
(12.44) 
 5 
54.40 
(11.52) 
 4 
92.00 
(13.47) 
 6 
72.67 
(12.24) 
 7 
83.43 
(9.91) 
 7 
91.43 
(13.55) 
MDADI-P 
 
4 
52.50 
(12.42) 
 5 
55.50 
(5.42) 
 4 
76.88 
(12.81) 
 6 
58.33 
(8.16) 
 7 
71.07 
(13.53) 
 7 
72.86 
(19.06) 
Note. CRT = chemoradiotherapy; E = emotional; F = functional; G = global; MDADI = MD Anderson Dysphagia 
Inventory; mo = month; P = physical 
 
Due to missing data, difference scores were only obtainable for three patients in the C-
PSE group and six patients in the ID-PSE group. Between-group differences in the post-RT/CRT 
phase were therefore, tested on the raw scores using the Mann-Whitney U test. Visual inspection 
of the data showed no significant differences between the two groups at three months post-
RT/CRT, but there was a pattern of better MDADI scores in the ID-PSE group than the C-PSE 
group on all of the MDADI subscales at one month post-RT/CRT (Figures 16-196). The Mann-
Whitney U test confirmed this difference to be significant for the MDADI-E (U = 31.5, z = 2.29, 
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p = .009, r = .66), the MDADI-F (U = 35, z = 2.85, p = .002, r = .82), and the MDADI-P (U = 31, 
z = 2.20, p = .015, r = .64), each of which had large to very large effects sizes. There was no 
significant difference in MDADI-G scores (U = 21, p = .320).  Mean ranks for the MDADI during 
the post-RT/CRT phase are presented in Table 17. 
In summary, the evidence indicates that patients in the ID-PSE group improved 
swallowing function more rapidly in the first month following RT/CRT than patients in the C-
PSE group. By three months post, this difference between the groups was no longer evident, 
indicating that the C-PSE group had caught up to the ID-PSE group regarding swallowing 
function. 
Table 17 
 
Mean ranks for MDADI subscale scores at the final-RT session, one month post-RT/CRT, and three 
months post-RT/CRT. Z-score, p-value, and effect size determined by Mann-Whitney U test 
 
 C-PSE Group     ID-PSE Group     
 
N 
Mean 
Rank 
 N 
Mean 
Rank 
z-score U 
p-value  
(1-tailed) 
Effect size 
(r) 
MDADI-Global          
      Final-RT 4 3.50  6 6.83 1.94 20.00 .057 .61 
     1 month-post 5 3.80  7 8.83 2.20 21.00 .312 .64 
     3 month-post 4 6.75  7 5.57 -.665 11.00 .324 -.20 
MDADI-Emo.          
Final-RT 4 3.25  6 7.00 1.92 21.00 .034* .61 
     1 month-post 5 3.70  7 8.50 2.29 31.50 .009* .66 
     3 month-post 4 6.12  7 5.93 -.097 13.50 .463 -.03 
MDADI-Funct.          
Final-RT 4 4.75  6 6.00 .644 15.00 .305 .20 
     1 month-post 5 3.00  7 9.00 2.85 35.00 .002* .82 
     3 month-post 4 5.88  7 6.07 .103 14.50 .50 .03 
MDADI-Physical          
Final-RT 4 5.00  6 5.83 .430 15.00 .381 .14 
     1 month-post 5 3.80  7 8.43 2.20 31.00 .015* .64 
     3 month-post 4 6.25  7 5.86 -.189 13.00 .463 -.06 
Note. NA = not applicable, MDADI = MD Anderson Dysphagia Inventory; RT = radiotherapy 
*Significant at alpha level = .05 
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Figure 15. Mean MDADI-Global post-RT/CRT scores        Figure 16. Mean MDADI-Emotional post-RT/CRT scores 
 
Figure 17. Mean MDADI-Functional post-RT/CRT scores          Figure 18. Mean MDADI-Physical post-RT/CRT scores 
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 Swallowing Pain.  Swallowing pain was measured on a scale from 0 (i.e., no pain) to 5 
(i.e., excruciating pain). Mean pain rating increased relatively steadily throughout RT/CRT and 
gradually declined during the post-RT/CRT phase for both groups. Mean pain during RT/CRT for 
the C-PSE and ID-PSE groups were 1.67 vs. 1.78 at RT 12-14, 2.22 vs. 1.89 at RT 23-25, and 
1.89 vs. 2.44 on the last day of RT, respectively.  During the post-RT/CRT phase, mean pain 
scores for the C-PSE and ID-PSE groups were .89 vs. .88 at one month post-RT/CRT and .14 vs. 
1.00 at three months post-RT/CRT, respectively. Visual inspection of the data (Figure 19) 
indicated a potential significant difference between the groups at the final-RT session and three 
months post-RT/CRT, both favoring the C-PSE group.  Mann-Whitney U test on the raw scores 
failed to show a significant difference between the groups for the last day of RT (U = 51.5, p = 
.17), but confirmed a significant difference at three months post-RT/CRT (U = 39, z = 2.109, p = 
.037, r = .56). Contrary to our hypothesis, this indicates that swallowing pain was actually worse 
in the ID-PSE group than the C-PSE group. However, it is relevant to note that patient 13 was 
again an outlier in the ID-PSE group, and as such, contributed to this difference. At three months 
post-RT/CRT patient 13 had a pain score of 3, while everyone else in the ID-PSE group as well as 
the C-PSE group had a pain score of 0 or 1. With patient 13 removed from the data, the difference 
between the groups approached but was not significant (U = 32, p = .07). Mean ranks and 
significance levels (patient 13 included) are presented in Table 18.  
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Table 18 
 
Mean swallowing-pain scores, standard deviations, ranges, and mean ranks at RT 12-14, RT 23-25, Final 
RT, one month post-RT/CRT, and three months post-RT/CRT. Pain scores based on 0-5 scale (i.e., 0 = no 
pain, 1 = mild pain, 2 = moderate pain, 3 = moderate to severe pain, 4 = severe pain, 5 = excruciating 
pain)  
 C-PSE ID-PSE 
 
N 
Mean Pain  
(SD) 
Range 
Mean 
Rank 
N 
Mean Pain 
(SD) 
Range 
Mean 
Rank  
z-score p-value 
(1-tailed) 
Effect 
size (r) 
RT 12-14 
9 
1.67 
(1.11) 
0-3 9.61 9 
1.78 
(1.09) 
1-4 9.39 -.092 .466 -.02 
RT 23-25 
9 
2.22 
(1.64) 
0-4 10.06 9 
1.89 
(1.36) 
0-4 8.94 -.454 .333 -.12 
Final RT 
9 
1.89 
(1.36) 
0-4 8.28 9 
2.44 
(1.13) 
1-4 10.72 1.01 .170 .24 
1 month 
post 
9 
.89 
(.93) 
0-3 8.72 8 
.88  
(.64) 
0-2 9.31 .274 .408 .07 
3 month 
post 
7 
.14 
(.38) 
0-1 5.43 7 
1.00 
(1.00) 
0-3 9.57 2.109 .037* .56 
Note. CRT = chemoradiotherapy; RT = radiotherapy; SD = standard deviation 
*Significant at alpha = .05 
 
 
 
Figure 19. Mean swallowing pain scores per group at RT 12-14, RT 23-25, final-RT, one month 
post-RT/CRT, and three months post-RT/CRT. mo = month, RT = radiotherapy 
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Chapter 5: Discussion 
The purpose of this study was to contribute to the evidence-base of prophylactic care for 
patients with RT/CRT-toxicity-induced dysphagia secondary to HNC.  The study sought to investigate 
the efficacy of a prophylactic swallowing exercise (PSE) program involving solely indirect swallowing 
exercises (ID-PSE) for the purpose of creating an effective PSE program that is more comfortable for 
patients, improves compliance, and maximizes swallowing function.  The ID-PSE program was 
compared to a more traditional PSE program that consisted of a combination of direct and indirect 
swallowing exercises (C-PSE). 
 Alternate assignment was used to place eighteen patients in either the C-PSE (n = 9) or ID-PSE 
(n = 9) group. Patients in both groups began their exercises within two weeks of beginning RT/CRT 
and were encouraged to continue the exercises throughout RT/CRT.  Patients in the C-PSE group were 
prescribed the effortful swallow, Mendelsohn maneuver, Masako maneuver, and the Shaker exercise.  
Patients in the ID-PSE group were prescribed the Shaker, pharyngeal squeeze, tongue-base retraction, 
and lingual and jaw range-of-motion exercises. All exercises were completed three times per day (see 
the Methods section for exact dose per exercise session for each exercise). Outcome measures, 
including the Eating Assessment Tool (EAT-20), Functional Oral Intake Scale (FOIS), percent PEG-
tube use, MD Anderson Dysphagia Inventory (MDADI), and swallowing pain, were collected at 
baseline, three times during RT/CRT, and at one month and three months post-RT/CRT.  There were 
no statistically significant differences between the groups in baseline outcome measures, 
demographics, cancer characteristics, or cancer treatment. We hypothesized that the ID-PSE program 
would minimize swallowing pain and subsequently would result in improved PSE compliance, 
improved oral intake, improved swallowing function, and less swallowing pain relative to the C-PSE 
group.  
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Compliance 
 We hypothesized that patients in the ID-PSE group would be more compliant to their PSE 
program than patients in the C-PSE group because the ID-PSE program would be more comfortable 
due to not having to swallow during the exercises. Although compliance in the ID-PSE group was 
higher than in the C-PSE group during the pre-RT phase and for the first four weeks of RT/CRT, the 
difference was not statistically significant.  The hypothesis, therefore, was not confirmed. Both groups 
were between 40-50% compliant overall and both groups generally declined in compliance throughout 
RT/CRT.   
The pattern of gradual decline in compliance throughout RT/CRT is consistent with all other 
PSE studies that report on compliance (Carnaby-Mann et al., 2011; Kotz et al., 2012; van der Molen et 
al., 2011; Virani et al., 2015). Overall rate of compliance was consistent van der Molen et al. (2011), 
who also reported an average compliance of around 40%. Carnaby-Mann et al. (2011), however, 
reported average compliance of 68% overall.  The factor that may have contributed to Carnaby-Mann 
et al.’s improved compliance relative to the current study was frequency of meetings with a speech-
language pathologist (SLP).  Carnaby-Mann et al. reported that a research SLP met with patients twice 
daily throughout the first six weeks of CRT to complete swallowing exercises. In the current study 
patients were relied upon to complete their swallowing exercises independently at home; an SLP only 
met with patients three times during RT/CRT to collect data. This is consistent with literature that 
indicates that supervised exercise programs result in better compliance and better outcomes than 
unsupervised exercise programs (Koh, Saxena, Ng, Yong, & Fong, 2012; Olney et al., 2006; Sluijs et 
al., 1993). 
Additional factors discussed in the literature regarding exercise compliance that may have 
played a role in compliance in the current study include patients’ belief and perception of the potential 
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benefit of the exercise (Sluijs et al., 1993), and generally feeling ill (Cohen-Mansfield, Marx, & 
Guralnik, 2003). It may be that patients in the C-PSE group had a greater belief in the benefit of their 
PSE program than patients in the ID-PSE group. This makes sense given that during the training phase 
of the study the importance of swallowing was emphasized to all patients and one explanation of 
decreased swallowing function during RT/CRT was a reduction or avoidance of swallowing. Further, it 
may simply be that generally feeling fatigued and sick outweighed any other factors impacting 
compliance, which is consistent with literature indicating that the single greatest predictor of exercises 
compliance in the elderly is health and pain (Cohen-Mansfield et al., 2003).  
Lastly, it may be that the ID-PSE program was in fact not more comfortable than the C-PSE 
program. In hindsight, it would have been prudent to ask patients a specific question about comfort 
level with the PSE program rather than only asking about pain with swallowing. Anecdotally, some 
patients in the ID-PSE group did report that towards the end of RT/CRT completing the exercises was 
painful. It is likely that mucositis-related pain is severe enough that not only swallowing, but also 
simply moving oral and pharyngeal structures is painful.  
Oral Intake 
 The second hypothesis of the study was that patients in the ID-PSE group would have better 
oral intake outcomes than patients in the C-PSE group.  Oral intake outcomes were measured with 
percent PEG-tube use, the FOIS, and PEG-tube discontinuation rates. The data failed to support the 
hypothesis. There were no significant differences in any oral intake outcomes between the two groups 
at any time point.  
Functional Oral Intake Scale. Outcomes on the FOIS were consistent with several prior PSE 
studies.  Carnaby-Mann et al. (2011), van der Molen et al. (2011), and Virani et al. (2015) all also 
found no differences in FOIS scores between different types of PSE. This may indicate that the FOIS is 
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not sufficiently sensitive to detect differences in oral intake, particularly given that each of these 
authors found significant differences between treatment groups on other outcome measures. In the 
current study, mean FOIS score for both groups combined was 4.29 at one month post-RT/CRT 
(median = 4) and 6 at three months post-RT/CRT (median = 6.5).  These rates are comparable to van 
der Molen et al. (2011), who reported a mean FOIS of 5 at 10 weeks post-RT in patients completing 
PSE and Kotz et al. (2012), who reported a median FOIS of 7 at three months post-RT in patients 
complete PSE. 
PEG-tube dependence. PEG-tube dependence rates were also comparable to other PSE 
studies. In the current study, overall PEG-tube dependence at three months post-RT/CRT was 
equivalent across the two groups at 12% (1/8) for each group. This rate was slightly better than Virani 
et al. (2015), who reported a PEG-dependence rate of 16% at three months post-RT/CRT in patients 
completing several PSEs. Further, Virani et al.’s comparison group, who’s PSE consisted of repetitive 
swallowing, had a PEG-dependence rate of 50% at three months post-RT/CRT, which is much worse 
than the current study’s rate of 12%. Additionally, the current study’s PEG-dependence rate of 12% at 
three months post is much better than the typical rate of 50% or higher in patients who do not complete 
any PSEs (Greven et al., 2008; Logemann et al., 2008).  
In summary, although the current study did not find evidence of a difference in oral intake 
outcomes between the two treatment groups, results of both groups are comparable to other PSE 
studies and better than patients who do not complete PSEs.  This is an indication that both PSE 
programs were effective in regards to improving oral intake outcomes relative to previous studies.  
Swallowing Function 
 In regards to swallowing function, we hypothesized that patients in the ID-PSE group would 
report better swallowing function than patients in the C-PSE group. This hypothesis was tested using 
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two self-reported swallowing-function outcome measures – the Eating Assessment Tool (EAT-20) and 
the MD Anderson Dysphagia Inventory (MDADI). Both tools were divided into emotional, functional, 
and physical subscales.  The MDADI also included a global subscale and the EAT-20 also included a 
total score.  
Although between-group differences were not evident on every subscale of either the EAT-20 
or the MDADI, the ID-PSE group had significantly better scores on four (i.e., EAT-20-Total, MDADI-
E, MDADI-F, and MDADI-P) of the eight total subscales at one month post-RT/CRT, and scores on 
the EAT-20-P approached significance (p = .065). This evidence is an indication that patients in the ID-
PSE group recovered swallowing function faster in the first month post-RT/CRT than patients in the C-
PSE group, which supports the hypothesis. This is the first PSE study to show a difference in outcomes 
as early as one month post-RT/CRT. Other PSE studies do not show a difference between groups until 
three months post-RT/CRT or later (Carnaby-Mann et al., 2011; Carroll et al., 2008; Kotz et al., 2012; 
van der Molen et al., 2011; Virani et al., 2015).   
 No prior PSE studies included the EAT-20, preventing cross-study comparison on that 
measure.  However, two prior PSE studies included the MDADI. Virani et al. (2012) reported MDADI 
scores on HNC patients immediately post-RT/CRT. MDADI scores on the last day of RT in the current 
study were very similar to Virani et al.’s post-RT/CRT scores with global mean scores of 48 vs. 42, 
emotional mean scores of 69.7 vs. 72.3, functional mean scores of 70 vs. 64, and physical mean scores 
of 56 vs. 55.3, respectively. Kulbersh et al.’s (2006) MDADI scores were obtained six to 12 months 
following RT/CRT. Those scores (global: 71.6, emotional: 71.5, functional: 68.3, and physical: 48.8) 
were slightly lower than the overall mean MDADI scores at three months post-RT/CRT in the current 
study (global: 87.3, emotional, 93.6, functional: 91.6, physical 74.3), indicating that patients in the 
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current study had better self-perceived swallowing function at three months post-RT/CRT than patients 
in the Kulbersh et al.’s study had at one year post-RT/CRT.  
In comparison to literature that includes MDADI outcomes in HNC patients who did not 
receive PSE, the current study showed favorable results. Gillespie, Brodsky, Day, Lee, and Martin-
Harris (2004) reported MDADI scores on patients treated with CRT for oropharyngeal cancer at 12 
months post-CRT. Their scores were slightly lower than MDADI scores in the current study at three 
months post-RT/CRT with MDADI global scores of 80 vs. 87.3, emotional scores of 76.8 vs. 93.6, 
functional scores of 86.4 vs. 91.6, and physical scores of 64.5 vs. 74.3, respectively. 
Overall, patients in the current cohort had better self-perceived swallowing function as 
measured by the MDADI than patients in both Kulbersh et al. (2006) and Gillespie et al. (2004); 
however, these are not entirely fair comparisons given that by 12 months post-RT/CRT patients in both 
Kulbersh et al. and Gillespie et al.’s study may have developed worsening dysphagia due to late-effects 
of RT/CRT.  
Swallowing Pain  
 We hypothesized that patients in the ID-PSE group would report less swallowing pain than 
patients in the C-PSE group because patients in the ID-PSE group did not have to swallow during their 
PSEs.  The analysis of the data, however, indicated that the only difference in swallowing pain between 
the two groups was at three months post-RT/CRT, at which point the ID-PSE group actually had more 
swallowing pain than the C-PSE group. We suspected that this statistical difference was primarily due 
to patient 13 who was an outlier in the ID-PSE group; however, removing patient 13 only slightly 
increased the p-value above the significance level (i.e., .07). Explaining this difference between the two 
groups is difficult.  Further study is necessary to ensure this is a valid finding and to explore potential 
reasons for the difference between the two groups. As discussed above, since the purpose of designing 
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
82 
 
a PSE program consisting solely of indirect swallowing exercises was to make the program more 
comfortable, it would have been more telling to ask patients to rate their comfort level while 
performing the PSEs, rather than rating swallowing pain in general.  The lack of between-group 
differences in swallowing pain was likely due to the severity of pain caused by mucositis outweighing 
any additional impact of the PSEs on swallowing pain.  
Relative to the literature, swallowing pain in the current study was comparable to van der 
Molen et al. (2011) who reported that 45% of patients had no swallowing pain at 10 weeks post-CRT. 
In the current study, 29% of patients overall had no pain at four weeks post-RT/CRT and 57% had no 
pain at three months post-RT/CRT.   
Limitations 
 Several limitations to this study should be considered when determining the strength of the 
conclusions drawn from the study. These limitations included a small sample size, the lack of a no-
treatment control group, the late addition of the MDADI, and the lack of an instrumental swallowing 
evaluation during the post-RT/CRT phase to objectively assess swallowing function. Additionally, the 
inclusion criteria, and what data and how the data was collected, had inherent limitations. 
The limitation in sample size is a common challenge when doing human-subject research on 
disordered populations, particularly in relatively rural communities such as Missoula, MT. The small 
number of patients in each group certainly negatively impacted the statistical power of the analysis and 
the subsequent confidence regarding the results. Impacting this issue further was the late addition of the 
MDADI and attrition, both of which contributed to even lower sample sizes in the post-RT/CRT phase. 
The trend favoring the ID-PSE group provides a strong rationale for continuation of this project; 
however, expansion of the current study, as well as replication of the results are necessary before firm 
conclusions can be made.  
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 The lack of a post-RT/CRT instrumental swallowing assessment limits the confidence in 
conclusions made regarding post-RT/CRT swallowing function; however, there were several reasons 
for not including an instrumental swallowing study post-RT/CRT.  First, HNC patients have been 
treated in this region for numerous years without regular post-RT/CRT instrumental swallowing 
assessments and without any clear negative outcomes as a result. It was, therefore, difficult to argue the 
need for an instrumental assessment for every patient unless that assessment could be provided free-of-
charge, which was not feasible, given that it would not have been possible for the principle investigator 
to conduct all instrumental studies, due to some patients not tolerating a FEES exam. Additionally, 
having multiple SLPs conducting the instrumental studies would have reduced the reliability of the 
results.  The MBS in particular has been shown to have poor inter-rater reliability (Stoeckli, Huisman, 
Seifert, & Martin–Harris, 2003; Wilcox, Liss, & Siegel, 1996). 
In hindsight, it may have been warranted to include in the inclusion criteria that all patients 
have functional swallowing ability at baseline to meet 100% of their nutritional needs. Intuitively, this 
makes sense given that the overarching topic of this research is prophylactic intervention and 
prescribing swallowing exercises for patients who already have severe dysphagia would not be 
considered prophylactic. Fortunately, only one patient in the study started with severe dysphagia, and 
although she was an outlier within the ID-PSE group, her scores did not appear to have a significant 
impact on the analysis. However, additional patients with non-functional swallowing at baseline may 
have a significant impact on our ability to infer results for patients who begin with functional 
swallowing ability and vice versa. Researching patients who start with severe dysphagia separately 
from those who do not, may provide more insight into the effectiveness of early dysphagia intervention 
for each respective group. 
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As already mentioned, asking patients to rate swallowing pain rather than pain while doing the 
swallowing exercises limited our ability to interpret comfort level of each PSE program. It likely would 
have been more telling to ask patients about comfort, specifically while doing the swallowing 
exercises.  
Furthermore, it may have been better to use the EAT-10 rather than the EAT-20 given that the 
EAT-10 had better reliability ratings than the EAT-20, and given that the EAT-20 did not have 
normative internal consistency data for the emotional, physical, and functional subscales. Analysis of 
the subscales using Chronbach’s alpha and the data gathered in this investigation provided acceptable 
correlation levels within each subscale; however, due to the small sample size in this investigation, the 
results of the Chronbach’s  should be interpreted with caution. Using the EAT-10 would have also 
reduced the time needed when gathering data from patients.  This was particularly relevant when 
obtaining data in the middle and final stages of RT/CRT when patients were very sick.  Patients’ poor 
emotional and physical condition may have impacted their answers when giving data.  Specifically, 
they may have rushed to complete the process more quickly.  Using a shorter outcome measure such as 
the EAT-10 may have minimized this potential confound.  
 The inclusion of the Shaker exercise in both PSE programs could also be considered a 
weakness and warrants discussion. The Shaker exercise was included in both groups at the principal 
investigator’s (PI) discretion due to the validity of the Shaker exercise for improving hyolaryngeal 
elevation and excursion and improving upper esophageal sphincter opening (Easterling et al., 2005; 
Logemann et al., 2009; Mepani et al., 2008; Shaker et al., 2002), both of which are common 
impairments in HNC patients (Hutcheson et al., 2008; Kotz et al., 2004; Logemann et al., 2008). This 
evidence, as well as the PI’s clinical anecdotal evidence, compelled her to include the Shaker in both 
programs so that each patient could benefit from it. The concern of including the Shaker exercise in 
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both programs was that it could have resulted in equivalent outcomes in both groups, had the Shaker 
been the primary contributor to the outcomes. However, this was not case, and therefore, inclusion of 
the Shaker in both programs should not take away from any of the conclusions. Certainly, it is possible 
that both groups benefitted from the Shaker and, therefore, between-group differences were smaller 
than they would have been had the Shaker not been included in the C-PSE group.  
Adding a no-treatment control group certainly would have added confidence to the conclusions 
made based on the study results; however, ethically this was not possible given that sufficient evidence 
warrants use of a PSE program for all HNC patients undergoing RT/CRT (Carnaby-Mann et al., 2011; 
Carroll et al., 2008; Kotz et al., 2012; van der Molen et al., 2011; Virani et al., 2015). As discussed 
above, in comparison to the no-treatment control groups in prior PSE studies, and in comparison to 
non-PSE studies, the outcomes from both groups in the current study were better than outcomes of 
patients not completing PSEs. 
Lastly, the investigators found it challenging to reliably measure compliance with the exercise 
programs. Patients frequently forgot to bring their exercise-tracking sheet to the data collection session 
or the sheet was not filled in correctly or completely. This was particularly the case during the initial 
months of the study.  In the later stages of the study, the investigator emphasized the importance of 
obtaining accurate compliance data, which improved the reliability of patients providing such data. It is 
also impossible to know if the compliance data provided by patients was accurate. Patients may have 
had a tendency to inflate their compliance to avoid disappointing the researcher.  
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Chapter 6: Conclusions  
Clinical Implications  
This study provides additional insight in developing an optimal prophylactic dysphagia 
treatment for patients with HNC undergoing RT with or without adjunctive chemotherapy. This study 
compared a unique PSE program, an indirect (non-swallowing) exercise program (ID-PSE), to a more 
common PSE program that consists of both direct and indirect swallowing exercises (C-PSE).  The 
results indicated that patients who completed ID-PSE had better self-perceived swallowing function 
and swallowing-related QOL as measured by the EAT-20 and the MDADI at one month post-RT/CRT 
than patients prescribed C-PSE. Interestingly, although this outcome supported the hypotheses in the 
study regarding swallowing function, the researchers hypothesized that improved swallowing function 
outcomes in the ID-PSE group would be due to improve compliance with an ID-PSE program, which 
was not found. It is not clear why the ID-PSE group performed better than the C-PSE group.  The two 
PSE programs were relatively balanced in physiological targets and dosage, other than the ID-PSE 
program including an exercise for jaw range of motion and the C-PSE program not including such an 
exercise.  However, it is difficult to imagine how this difference could explain the difference in 
swallowing function outcomes, particularly because none of the patients in the C-PSE group 
complained of significantly reduced jaw function, nor was reduced jaw function observed visually. 
Certainly it is possible that patients in the C-PSE group had reduced jaw mobility relative to patients in 
the ID-PSE group but a slight reduction in jaw mobility would not explain significant changes in 
overall swallowing function.  
 One likely explanation for the difference between the groups is the relative simplicity of the ID-
PSE program over the C-PSE program, which likely contributed to patients completing the ID-PSE 
program more accurately than the C-PSE program. The effortful swallow in the C-PSE program can be 
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particularly challenging for patients to do accurately and accuracy of the effortful swallow is difficult to 
assess without surface electromyography (Huckabee & Steele, 2006). Additionally, clinical experience 
indicates that the effortful swallow and the Mendelsohn maneuver are the most vulnerable swallowing 
exercises to be done incorrectly when a patient is fatigued and weak. Whereas, it is difficult to imagine 
how any of the ID-PSE exercises would have been significantly impacted by fatigue or weakness.  
Therefore, accurateness of the exercises, rather than the specific exercises themselves, may have 
contributed to the outcomes. A study contrasting a home PSE program with minimal monitoring of 
accuracy of each exercise (as in the current study) versus the same program with regular assessment of 
exercise accuracy would help answer this question. 
 This study provides preliminary evidence that a PSE program consisting solely of indirect 
exercises may be as effective as a PSE program consisting of a combination of direct and indirect 
swallowing exercises.  This is a particularly interesting finding in light of principles of neuroplasticity, 
which indicate that direct (i.e., specific) exercises are more beneficial than indirect (i.e., non-specific) 
exercises (Kleim & Jones, 2008; Robbins et al., 2008). This study, and the many unanswered questions 
that follow it, by no means negate these current established principles of neuroplasticity; however, it 
does highlight the need for continued research in the area.  
An additional clinical implication of the study applies to patients with severe dysphagia. Many 
patients with severe dysphagia are unable to reliably perform direct swallowing exercises due to 
inability to reliably elicit a swallow. This study provides additional evidence for the benefit of indirect 
swallowing exercises for these patients in particular.  
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Future Directions 
This line of research is truly in its infancy. The current evidence base has primarily 
demonstrated proof-of-concept, safety, and feasibility. Hula, Cherney, and Worrall (2013) lay out a 
useful sequence for continued treatment efficacy research. Additional Phase 1 studies are needed to 
determine specification of a PSE protocol as well as optimal outcome measures. Research in this vein 
will answer questions regarding the most optimal swallowing exercises, the optimal dose and dose 
frequency of those exercises, the ideal timing of onset of a PSE program, and the most optimal 
outcome measures to be used in subsequent Phase II trials. Phase II trials can then commence to 
establish treatment efficacy. Phase II trials should include randomized control trials with an emphasis 
on making inferences at the population level using highly controlled research environments. There are 
many population factors that will need to be considered and controlled for in Phase II trials including 
tumor size and location, cancer stage, the presence of pre-RT/CRT surgery, age, gender, etc.  The final 
two phases recommended by Hula et al. (2013) include Phase III trials, which are designed to 
determine treatment effectiveness under typical clinical practice conditions, and Phase IV trials, which 
have a goal of determining the need for change to standard health service delivery models or policy. 
Phase IV trials focus on answering questions surrounding cost-effectiveness and cost-benefit ratios.    
There are also a whole host of psychosocial factors that play a role in treating patients with 
HNC. These factors will likely play a role in future research. As an example, anecdotally we observed 
that patients with a strong support network were more compliant with exercises and dealt with the 
negative impacts of RT/CRT better than patients who did not have a strong support network. Given this 
observation, we recommend that future research consider these factors, how they impact swallowing 
function outcomes, and how to identify at-risk patients due to poor social support. 
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Appendices  
 
Appendix A 
Permission to be Contacted Form 
 
Return this form to: 
 
Attn:  Laurie Slovarp 
           CSD Department 
           Fax:  406-243-2362 
        
 
Study Title:     
Preventative Dysphagia Intervention for Patients with Head and Neck Cancer receiving Chemoradiation Therapy (CRT) 
 
Investigator(s):  
Laurie Slovarp M. S., SLP-CCC, BRS-S, The University of Montana, Department of  
 Communicative Sciences and Disorders (CSD 031), (406)243-2107 
 
Purpose 
 You are being asked to be contacted by researchers at the University of Montana, to learn more about taking part in 
a research study comparing two different exercise programs used to help prevent or minimize dysphagia (an impairment in 
the ability to swallow). This study is designed to help develop an optimal treatment protocol that minimizes the prevalence 
and degree of dysphagia in patients treated with chemoradiation therapy (CRT) for oral, pharyngeal, and/or laryngeal cancer, 
while also minimizing discomfort.  
 
Statement of consent to be contacted by the researchers: 
 
 I, __________________________________, agree to be contacted by the researchers at The University of 
Montana  
                                (printed name) 
for additional information on the above mentioned study.  I am in no way agreeing at this time to participate in the study.  
 
You may contact me via: 
 
  Phone: _________________________________ 
 
  Email: _________________________________ 
  
             
 
                                                                           ________________________                     
Patient Signature      Date 
 
 
 
Patient’s projected start date of radiation therapy: _____________________  
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Appendix B 
 
NUTRITIONAL AND PAIN QUESTIONAIRE 
Participant code: ___________________________  Date:________________________ 
Current Weight: _____________________ 
 
Tube Feeding Use: 
Do you currently have a tube inserted into your stomach for nutrition? Mark the correct answer 
 Yes        No 
  
If yes, please answer the following question.  If no, please skip to pain rating section. 
  
Approximately, what percentage of your daily 
food intake is consumed using your tube? Swallowing Pain Rating:  
Check one option: 
Please use the following scale to indicate the amount 
of pain you have with swallowing.  
 
 0-10%  0 (no pain) 
 10-25%  1-2 (mild discomfort) 
 25-50%  3-4 (moderate discomfort) 
 50-75%  5-6 (severe pain) 
 75-90%  7-8 (very severe pain) 
 90-100%  9-10 ( excruciating pain) 
 
Functional Oral Intake Scale (FOIS):  Please circle the diet level that best describes your nutritional 
intake.  
 
Category Level Description 
Non-Oral 
1 Nothing by mouth (NPO) 
2 Tube dependent with minimal attempts of food or liquid 
3 Tube dependent with consistent intake of liquid or food 
Full-Oral 
4 Total oral diet of a single consistency (e.g., all pureed foods) 
5 
Total oral diet with multiple consistencies but requiring special preparation or 
swallowing compensatory strategies 
6 
Total oral diet with multiple consistencies without special preparation, but with 
specific food limitations (e.g., avoiding dry foods) 
7 Total oral diet with no restriction (eat anything you would like)  
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Appendix C 
The M.D. Anderson Dysphagia Inventory 
 
Participant code: _______________________________     Date: ____________________ 
 
Week post-CRT start: __________________    Weeks/months post-CRT end: __________ 
 
 
Please read each statement and circle the response which best reflects your experience in the 
past week. 
 
1. My swallowing ability limits my day-to-day activities.   
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
2. (E2) I am embarrassed by my eating habits. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
3. (F1) People have difficulty cooking for me. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
4. (P2) Swallowing is more difficult at the end of the day. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
5. (E7) I do not feel self-conscious when I eat. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
6. (E4) I am upset by my swallowing problem. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
7. (P6) Swallowing takes great effort. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
8. (E5) I do not go out because of my swallowing problem.  
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
9. (F5) My swallowing difficulty has caused me to lose income. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
10. (P7) It takes me longer to eat because of my swallowing problem. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
11. (P3) People ask me, “Why can’t you eat that?” 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
12. (E3) Other people are irritated by my eating problem. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
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13. (P8) I cough when I try to drink liquids. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
14. (F3) My swallowing problems limit my social and personal life. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
15. (F2) I feel free to go out to eat with my friends, neighbors, and relatives. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
16. (P5) I limit my food intake because of my swallowing difficulty. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
17. (P1) I cannot maintain my weight because of my swallowing problem. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
18. (E6) I have low self-esteem because of my swallowing problem. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
19. (P4) I feel that I am swallowing a huge amount of food. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
 
20. (F4) I feel excluded because of my eating habits. 
 Strongly Agree        Agree       No Opinion     Disagree     Strongly Disagree 
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Appendix D 
 
Eating Assessment Tool (EAT – 20) 
 
Participant code: ___________________________  Date: ____________ 
 
Circle the appropriate response: 
To what extent are the following scenarios 
problematic for you?  
0 = No problem   
5 = Severe problem 
1. My swallowing problem has caused me to lose 
weight. 
0 1 2 3 4 5 
2. My swallowing problem interferes with my ability to 
go out for meals. 
0 1 2 3 4 5 
3.  My swallowing problem interferes with my work or 
other activities.  
0 1 2 3 4 5 
4.   Swallowing liquids takes extra effort.   0 1 2 3 4 5 
5.  Swallowing solids takes extra effort.  0 1 2 3 4 5 
6.  Swallowing pills takes extra effort 0 1 2 3 4 5 
7.  I have altered my diet because of my swallowing 
problem.  
0 1 2 3 4 5 
8.  Swallowing is painful.  0 1 2 3 4 5 
9.   The pleasure of eating is affected by my swallowing.  0 1 2 3 4 5 
10.  When I swallow food sticks in my throat.  0 1 2 3 4 5 
11.  When I swallow food sticks in my chest.  0 1 2 3 4 5 
12.  I cough when I eat.  0 1 2 3 4 5 
13.  I am afraid to eat because of my swallowing 
problem.  
0 1 2 3 4 5 
14.  My swallowing problem is a burden to my family.  0 1 2 3 4 5 
15.  I get tired when I eat.  0 1 2 3 4 5 
16.  I avoid eating in front of people.  0 1 2 3 4 5 
17.  I am afraid of choking in my sleep.  0 1 2 3 4 5 
18.  I become short of breath when I eat.  0 1 2 3 4 5 
19.  People perceive me as sick because of my 
swallowing problem.  
0 1 2 3 4 5 
20.  Swallowing is stressful.  0 1 2 3 4 5 
       TOTAL 
  
TWO PROPHYLACTIC-DYSPHAGIA INTERVENTIONS FOR HNC                                              
 
 
121 
 
Appendix E 
 
SUBJECT INFORMATION AND INFORMED CONSENT 
 
 
Study Title:   
Prophylactic Dysphagia Intervention for Patients with Head and Neck Cancer receiving 
Chemoradiation Therapy (CRT) 
 
Investigator(s):  
Laurie Slovarp M.S., SLP-CCC, BRS-S, The University of Montana, Department of  
 Communicative Sciences and Disorders (CSD 031), (406)243-2107 
Amy Glatt B. A., Research Assistant. The University of Montana,  Department of 
Communicative Sciences and Disorders (CSD), (406)243-2107 
 
 
Special instructions  
 
This consent form may contain words that are new to you.  If you read any words that are 
unclear to you, please ask the person who gave you this form to explain them to you. 
 
Purpose 
  
You are being asked to take part in a research study comparing two different exercise programs used to 
help prevent or minimize difficulty swallowing (called “dysphagia”). This study is designed to help 
develop a way to minimize the degree and discomfort of dysphagia in patients treated with 
chemoradiation therapy (CRT) for oral, pharyngeal, and/or laryngeal cancer. 
 
Procedures 
  
If you agree to take part in this research study you will be asked to  
 
1. undergo a baseline instrumental swallow study (modified barium swallow (MBS) or 
fiberoptic endoscopic evaluation of swallowing (FEES)),   
2. complete daily swallowing exercises throughout your radiation therapy, and 
3. periodically fill out a number of brief questionnaires to assess your swallowing function.  
 
You will be assigned to one of two treatment groups. Both treatment groups will be given a series of 
swallowing exercises.  Both types of exercise have been shown to be helpful for minimizing dysphagia 
during and after CRT.   
 
Swallowing exercise group: The exercises for this group will primarily emphasize swallow 
strengthening with primarily exercises that require you to swallow (see “Swallowing Exercises 
Handout”).    
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Non-swallowing exercise group: The exercises for this group will not require swallowing 
during the exercises; rather the exercises will focus primarily on flexibility of the muscles used 
during swallowing (see “Non-Swallowing Exercises Handout”).    
 
The following is a description of the timeline/phases of the study. 
 Baseline Instrumental Swallow Study:  Prior to beginning chemoradiation, you will 
undergo an instrumental swallow examination (either a Modified Barium Study (MBS) or 
a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), either of which are routinely 
recommended prior to beginning chemoradiation to the mouth, pharynx, or larynx)  
 Training Phase: You will be seen by the investigator(s) for 2-3 sessions for an initial 
interview and for training to learn how to perform your exercise program and how to track 
compliance to the program.  A paper tracking form will be provided and you will be asked 
to keep a daily record of your exercises.   
 Treatment Phase: Following the training phase, you will be seen once every two weeks 
throughout CRT (or more if necessary given the severity of your dysphagia) to document 
progress using a number of tools.  You will fill out three questionnaires that will provide 
the following information.  1) The amount of food you take via a feeding tube versus 
eating by mouth, 2) the amount of pain you are experiencing, and 3) behaviors, responses 
and quality of life related to swallowing.  
 Post-treatment Phase: After CRT, the investigators will see you as appropriate for 
dysphagia therapy until you return to full per oral (P.O., by mouth) intake with the least 
restrictive diet possible. Your dysphagia therapy at that point will be guided by the nature 
of your dysphagia and best practices.  You will be followed during this phase for three 
months.  If you do not need active dysphagia therapy during the entire three month period, 
you will be asked to fill out the data questionnaires via phone or mail once per month.   
 Long-term Phase: After you have been discharged from therapy, the principal 
investigator (Laurie Slovarp) will follow up with you at six months post-treatment (three 
months following the post-treatment phase) and 12 months post-treatment.  From that 
point on data collection will take place once per year for 10 years using the same data 
questionnaires used during the treatment and post-treatment phases.  A self-addressed, 
stamped envelope will be included for you to return them at no cost to you.  This should 
take you no more than 10 minutes.   
 
Risks/Discomforts 
 
You may experience pain, fatigue, frustration or aspiration (small amounts of food or liquid into your 
airway) during the therapy. The therapies chosen are considered safe and ethical practice and will not 
exceed the expected risks/discomforts from traditional dysphagia therapy.  You will be able to take 
short breaks during treatment to help allevieate any pain, fatigue, or frustration that may occur as a 
result of therapy. You also may drop out of the study at any time without any penalty or effect on your 
medical treatment or care.  The researchers will communicate with your medical team and will report 
any concerning effects that may warrant medical management, although it is highly unlikely that 
participation in this study will lead to any such effects.   
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Benefits 
   
There is no guarantee that you will receive any direct benefit from taking part in this study, but 
participation may minimize your swallowing impairment severity while and after you complete CRT.  
Specifically, the exercises chosen for the study have been shown to improve swallowing function 
following CRT (Carrol, Locher, Canon, Bohannon, McColloch, & Magnuson, 2008; Hutcheson & 
Lewin, 2012; Vander Molen, Van Rossum, Burkhead, Smeele, Coen, & Hilgers, 2011). You will also 
receive swallowing therapy from a certified Speech Language Pathologist.  Additionally, you will be 
contributing to the knowledge base on how best to treat patients with head and neck cancer who suffer 
from dysphagia. 
 
Payment 
 
There will be no cost to you for participating in this study and you will not receive payment for 
participating. However, costs that are related to the standard treatment for your dysphagia and not 
related to this research will be billed to you or your insurance company (i.e., modified barium swallow 
studies and swallowing therapy following completion of CRT).  If it is necessary for you to have 
additional swallowing therapy following completion of CRT,  and you are unable to pay for such 
therapy (e.g., uninsured or underinsured), you will have the option to receive therapy at no charge 
through the RiteCare Speech, Language, and Hearing Clinic at The University of Montana.   
 
Confidentiality 
 
Your identity and the information that is obtained about you during this study will remain confidential 
to the extent provided by law.  However, the study investigator, National Institute of Health, The US 
Food and Drug Administration (FDA), study staff, study sponsor, and the Joint Investigational Review 
Board may review your records to verify study related information.  If the study results are published or 
presented, you will not be identified by your name. 
   
Prior to the first screening, you will be given this research consent form, and HIPAA (Health Insurance 
Portability and Accountability Act) form. These will be the only forms containing your personal 
information (name, date of birth, address, phone number, email).  The consent form has a place to write 
in a non-identifiable participant code.  Your identification on all subsequent documents (other than the 
consent form and the HIPAA form) specifically pertaining to the research will be by the non-
identifiable code rather than your name and will be kept in a locked file cabinet in room 031 in the 
Department of Communicative Sciences and Disorders.  Consent and HIPAA forms, as well as 
medical records pertaining to standard dysphagia care that is outside the scope of the specific research 
protocol, will be kept in your therapy chart, which will be kept in a locked file cabinet.  This will 
ensure that coded data is not easily associated with your name.  Only the research team and necessary 
medical professionals outlined by the laws of HIPAA will have access to these files.  All data files will 
be identified with the same anonymous code and will be password protected.   
 
Compensation for Injury 
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Although we do not foresee any risk in taking part in this study, the following liability statement is 
required in all University of Montana consent forms:  “In the event that you are injured as a result of 
this research you should individually seek appropriate medical treatment.  If the injury is caused by the 
negligence of The University or any of its employees, you may be entitled to reimbursement or 
compensation pursuant to the Comprehensive State Insurance Plan established by the Department of 
Administration under the authority of M.C.A., Title 2, Ch 9.  In the event of a claim for such injury, 
further information may be obtained from The University’s Claims representative or University Legal 
Counsel.” (Reviewed by University Legal Counsel, July 6, 1993) 
 
It is not the regular policy of The University of Montana or Saint Patrick Hospital, the sponsor of this 
research study, to provide compensation for injury beyond what is stated in the above paragraph.  You 
still have all of your legal rights to seek other compensation. 
 
Pregnancy/Contraception 
 
You should not undergo a modified barium swallow (MBS) study if you are pregnant.  If you are 
pregnant, or become pregnant during the study, be sure to inform us.  If this does happen, you will be 
given the option to have endoscopic swallow study (FEES) study instead.  Your participation in this 
study poses no other risks pertaining to pregnancy or contraception  
 
Voluntary Participation/Withdrawal 
   
Your decision to take part in this research study is voluntary. You may refuse to take part in or you 
may withdraw from the study at any time without penalty or loss of benefits to which you are normally 
entitled. If you decide to withdraw, contact the lead investigator, Laurie Slovarp MS, SLP-CCC, BRS-
S at The University of Montana, Department of Communicative Sciences and Disorders (CSD 031), 
(406)243-2107. 
  
Questions 
 
This research study has been reviewed by the Joint Investigational Review Board (JIRB) for the 
purpose of protecting your safety and rights.  The JIRB was instituted under Federal and State law to 
review studies such as this one in order to protect research participants from: 
 unnecessary risks 
 risks that outweigh the benefits 
 procedures that are scientifically unnecessary 
 
If you have any questions regarding your rights as a research study participant, you may call the Joint 
Investigational Review Board (JIRB) Coordinator at (406) 329-5669.  
 
If you have any questions about the research procedures now or during the study contact: Laurie 
Slovarp, The University of Montana, Department of Communicative Sciences and Disorders 
(CSD 031), (406)243-2107.  
 
Video Recordings 
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We would like to videotape the study procedures.   Videotaping is completely voluntary.  Participants 
are free to withdraw their recordings from this study at any time without penalty and without 
jeopardizing future services at The University of Montana or Providence Saint Patrick Hospital.  We 
will provide an opportunity for you to review and edit the recordings if you request.  We may also want 
to use the recordings for future related research or for educational purposes.  Although the recordings 
will not be labeled with your name, someone who knows you may be able to identify you from the 
recordings.   
 
We would like your consent to the following specific uses of the video recordings made of you.  If you 
have any questions or concerns about the recordings or their use, you are free to restrict the uses 
described below.  Restrictions will not affect your participation in any current or future research studies 
or clinical services at the RiteCare Speech, Language and Hearing Clinic or at Saint Patrick Hospital. 
 
Do you consent to being video recorded for Research Purposes? (i.e., viewing/listening by The 
University of Montana faculty, students, and staff for research purposes)    
 Yes     No    initials: ____ 
 
Do you consent to being video recorded for the following educational Purposes? 
 Viewing/listening by The University of Montana faculty, students, and staff for education 
(e.g., course presentations, lectures, assignments, etc.)    
 Yes   No  initials: ____ 
 Viewing/listening by participants in any educational activities at the discretion of Speech 
Pathology and Audiology faculty and staff.  The educational activities include conferences and 
workshops attended by students, professionals, and caregivers.  The recordings may be shared 
through any medium, provided it is not available to the general public.                                       
 Yes    No  initials: ____ 
 Viewing/listening by the general public at activities or through media sponsored or licensed by 
The University of Montana, or its faculty or staff (e.g., Internet/World Wide Web, local 
television)?    Yes    No  initials: _____ 
 Viewing/listening by the general public through licensed commercial enterprises for 
educational or research purposes, for example a CD-ROM enclosed in a textbook.                                        
 Yes    No  initials: ____ 
 
Decline of Video/Audio Recording 
 If you would not like to be video or audio recorded, place your initials here _____. 
 
_________________________________________________________________________________ 
 
STATEMENT OF CONSENT  
If you agree to be a participant of this study, sign one of the following two consent statements:  
 
Statement of Consent to participate as a treatment participant  
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I have read the above description of this research study. I have been informed of the risks and benefits 
involved, and all my questions have been answered to my satisfaction.  Furthermore, I have been 
assured that any future questions I may have will also be answered by a member of the research team.  
I voluntarily agree to take part in this study.  I understand I will receive a copy of this consent form. 
 
By signing this consent form, I have not waived any of the legal rights which I otherwise would have 
as a participant in a research study. 
 
I voluntarily agree to participate in this study and authorize the use and disclosure of my private health 
information as outlined in this form.   
 
Participant Code:_________ 
 
Participant Name (printed): ________________________________  Date of birth: ____________  
 
Age: _______________   Gender:    male     female 
 
Address: ________________________________________________________________________ 
                   
Primary phone number:_______________________ Alternative phone:____________________ 
      
Email address: _________________________     Radiation Oncologist: _______________________ 
 
We may need to contact you regarding scheduling.  How may we contact you?  
 Telephone                   Text messaging      email 
 
Participant signature:                                                                           Date: __________________                     
 
Investigator Signature: ___________________________________________ 
 
 
Consent to participate only as a non-treatment control participant      
 
I decline to participate in the baseline, training and treatment phases of this study, but agree to 
participate as a non-treatment control participant.  I agree to answer the questionnaires at the same 
frequencies as the treatment participants.   
      
Participant Code:_________ 
 
Participant Name (printed): ________________________________  Date of birth: ____________  
 
Age: _________ Gender:    male      female  
 
Address: _________________________________________________________________________ 
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Primary phone number:________________________   Alternative phone:____________________ 
 
email address: _________________________     Radiation Oncologist: ________________________ 
 
How may we contact you?  
 Telephone                   Text messaging      email 
 
Participant signature:                                                                           Date: __________________                     
 
Investigator Signature: ___________________________________________ 
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Appendix F 
 
Prophylactic Dysphagia Intervention for Patients with Head and Neck Cancer Receiving 
Chemoradation Therapy (CRT) 
 
Authorization for Access to Personal Health Information 
 
A federal government rule has been issued to protect the privacy rights of patients.  The rule is designed to protect the 
confidentiality of your personal health information.  We are required by these new regulations to obtain your 
authorization to share personal health information that may reveal your identity.   
 
What Information will be Used or Disclosed 
For this research study, the health information to be used or disclosed includes information contained in your existing 
medical records and new information created or collected during this study.  Your records may include information 
about your physical examinations, medical procedures (e.g., surgeries, swallow studies, chemoradiation), medical 
history, and any other data collected or reviewed during the course of the study as described in the consent form.  
 
Purpose for Use or Disclosure 
The purpose for use or disclosure of information gathered will be to measure the effectiveness of the therapies being 
studied in this research and to develop a better understanding of how best to treat dysphagia in patients with head and 
neck cancer.  
 
Who May Use or Disclose Information 
The persons and organizations that may use or disclose your individually identifiable health information may include: 
your physicians, the study investigator (Laurie Slovarp) and investigator staff.    
 
Who May Receive Information 
The persons and entities that may receive your personal health information may include: National Institute of Health, 
The US Food and Drug Administration (FDA), and the Saint Patrick Hospital/Community Medical Center Joint 
Investigational Review Board.    
 
Every effort will be made to maintain confidentiality of information accessed.  However, absolute confidentiality 
cannot be guaranteed.  Once your personal health information is released it may be re-disclosed, at which point your 
health information will no longer be protected by federal privacy regulations. 
 
Duration of Authorization 
This authorization does not have an expiration date.  If you do not cancel this authorization, then it will remain in 
effect indefinitely.  
 
Right to Refuse, Withdraw or Cancel Authorization 
You may refuse to sign this authorization. If you refuse to sign this authorization, you will not be able to take part in 
this study.  However, you will not be penalized or lose any benefits to which you are otherwise entitled.  You will 
continue to receive treatment for your condition. 
 
You have the right to cancel this authorization or withdraw from this study at any time with no penalty.  If you 
choose to do so, you must notify the study investigator in writing at Laurie Slovarp, Department of Communicative 
Sciences and Disorders, The University of Montana, 32 Campus Dr., Missoula, MT 59812.  Data collected prior to 
cancellation of this authorization may be used in order to preserve the scientific integrity of the study. 
 
Patient Access to Records 
You have the right to access your medical records at any time.  However, you will not be able to access study specific 
information until the study is completed, at which time your right of access will be restored.  
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Privacy Authorization 
I have read this Privacy Authorization and have had my questions answered to my satisfaction at this time.  I 
understand that by signing this consent, I authorize the release of my medical records and health information related 
to this study.  I authorize the use, disclosure, review, duplication, storage and data transfer of my medical records and 
study information.  I understand this information may be obtained by the persons and organizations stated above.  I 
will receive a copy of this signed authorization. 
 
I authorize the following medical personnel/healthcare facilities to release my records.  
 
___________________________________  ____________   ________________ 
Name of Physician/Healthcare Facility                                                                    Telephone                                     Fax 
 
_____________________   ______________   _____________   _____________ 
Street Address                                               City,                                        State,                                     Zip Code 
 
 
___________________________________  ____________   ________________ 
Name of Physician/Healthcare Facility                                                                    Telephone                                     Fax 
 
_____________________   ______________   _____________   _____________ 
Street Address                                               City,                                        State,                                     Zip Code 
 
 
___________________________________  ____________   ________________ 
Name of Physician/Healthcare Facility                                                                    Telephone                                     Fax 
 
_____________________   ______________   _____________   _____________ 
Street Address                                               City,                                        State,                                     Zip Code 
 
 
_________________________________ _________ _____________________________  
Signature of Participant    Date  Name of Participant (Printed) 
 
Or 
 
_________________________________ _________ _____________________________ 
Signature of Legal Representative  Date  Name of Legal Representative (Printed) 
 
______________________________       
Relationship to Participant 
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Appendix G 
 
Swallowing Exercise Instructions 
C-PSE Group 
 
Mendelsohn 
When you swallow your throat elevates and then immediately drops back down. To do this, 
swallow and hold your throat up 2-3 seconds. To do this you will hold the contraction of the 
swallowing muscles. You have already swallowed so the food is gone, you are just not 
releasing the swallow. You will not be able to breathe while you are holding your throat up. Do 
this exercise 15 times in a row, 3 times per day, 7 days per week. 
 
Effortful Swallow 
When you swallow squeeze all you swallowing muscles as hard as you can. You can do this 
while swallowing anything. Do this exercise 20 times in a row, 3 times per day, 7 days per 
week. 
   
Masako 
Do this exercise when you only have saliva in your mouth. Place your tongue between your 
teeth and lightly bite down with enough force to hold your tongue in place. Be sure to keep 
your tongue between your teeth and swallow. Do this exercise 10 times in a row, 3 times per 
day, 7 days per week. 
 
Shaker 
This exercise has two parts.  Both parts requires the same type of motion.  Lie flat on your back 
without a pillow and lift your head so that your chin approaches your chest.  Do not lift your 
shoulders off of the ground. Try to look at your toes.  Part 1: hold your head up for one minute 
(or as long as you can).  Part 2: lift and lower your head 20 times holding at the top each time 
for just 1-2 seconds.  Do this exercise three times per day, 7 days per week. 
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Appendix H 
 
Swallowing Exercise Instructions 
ID-PSE group 
 
Shaker 
This exercise has two parts.  Both parts requires the same type of motion.  Lie flat on your back 
without a pillow and lift your head so that your chin approaches your chest.  Do not lift your 
shoulders off of the ground. Try to look at your toes.  Part 1: hold your head up for one minute 
(or as long as you can).  Part 2: lift and lower your head 20 times holding at the top each time 
for just 1-2 seconds.  Do this exercise three times per day, 7 days per week. 
 
Falsetto “ee” 
 Take a deep breath and then say a soft, high pitched “ee” sound as long as you can. Do this 
exercise 6 times in a row, 3 times per day, 7 days per week.  
 
Tongue-Base Retraction 
Stick your tongue out and grab it between your fingers with a washcloth. Then pull your tongue 
back into your mouth as far as you can, providing resistance by holding your tongue with the 
washcloth. You will likely have to stop to swallow intermittently. If you have trouble holding 
your tongue, you can just stick your tongue out and pull it in your mouth without resistance. If 
you do it this way, do it in front of a mirror and try to not curl your tongue tip. You should feel 
the back of your tongue touch the back of your throat. If it makes you gag, you likely did it 
correctly. Do this exercise 10 times, 3 times per day, 7 days per week. 
 
Lingual Range of Motion Exercises 
Stick out your tongue and move it up towards your nose and then down towards your chin.  
Stretch as far as you can in both directions.  Repeat 10 times, 3 times per day, 7 days per 
week. 
Move your tongue in a circle on the outside of all of your teeth (as if you are cleaning food off 
of the outer surface of your teeth).  Repeat 10 times, 3 times per day, 7 days per week. 
Press your tongue in to each of your cheeks (going back and forth).  Stretch as far as you can.  
Do this exercise 10 times, 3 times per day, 7 days per week. 
Jaw Range of Motion Exercises  
Open your mouth as far as you can and hold for 2-3 seconds, close and repeat.  Do this 
exercise 10 times, 3 times per day, 7 days per week.  
Move your jaw from side to side as far as you can each way. Do this exercise 10 times, 3 
times per day, 7 days per week.  
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Appendix I 
 
Swallowing Exercise Tracking Sheet 
 
Instructions: List the number of repetitions and sets of each exercises you performed each day. If you did not complete a set of exercises please list 
which exercise it was and why you could not perform it. 
Participant Number: 
Exercises 
(S) Mendelsohn 
Effortful 
Swallow Masako Shaker Comments: 
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:           
Date:      
Date:      
Date:      
Date:      
Date:      
Date:           
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Appendix J 
 
Swallowing Exercise Tracking Sheet 
 
Instructions: List the number of repetitions and sets of each exercises you performed each day. If you did not complete a set of exercises please 
list which exercise it was and why you could not perform it. 
 
Participant Number:  
Exercises 
(NS) Shaker 
Falsetto 
“ee” 
Tongue-
Base 
Retraction 
Tongue 
Range 
of 
Motion 
Jaw 
Range 
of 
Motion Comments: 
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:            
Date:       
Date:       
Date:       
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